question manag team
ahead annual credit suiss healthcar confer compil list relev
question topic discuss respect manag team across divers
coverag univers healthcar compani pleas contact research analyst copi
latest model request prepar meet scottsdal arizona
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
tabl content
labcorp america lh
david fletcher telehealth geising not-for-profit
think compani come year
expect three quarter report novemb
surpris play expect
better wors
report result last week discuss challeng
encount us busi otherwis perform well briefli
describ happen compani respond challeng
also highlight disrupt hurrican california wildfir
primarili short term issu need move patient around actual
damag facil impact result time futur ebitda
impact rel modest mln understand
length stay y/i that littl bit ytd trend
anyth unusu call lo impact oper challeng
updat us length stay trend within servic line fairli steadi one
peer regularli discuss pressur lo seen increas
manag medicaid penetr busi experienc
overview busi
step back bit broadli give us brief overview differ line
busi us well size growth rate busi
and/or market sometim peopl think behavior health broad sens
good get baselin differ type servic offer
uk busi differ line busi larg
industri and/or compani growth rate area
your look ad bed exclud acquisit specif
necessarili longer period year mani bed expect
add exist facil de novo joint ventur
mani de novo and/or jv pipelin right
expect timelin project
view sustain organ growth rate us uk
acquisit pipelin like point larg deal
look would look mainli small tuck-in deal acadia
updat us see term payment rate updat
major payer categori commerci medicar medicaid signific
payment differenti medicar fee-for-servic medicaid fee-for-servic
medicaid manag care
seem regularli recur tight suppli clinician
behavior health space us uk kind y/i wage increas
see behavior nurs tight suppli behavior nurs
psychiatrist constrain growth way
remind us stand uk sale process expect solicit bid
earli mean overal length time process could take
could look announc end would mid-
year timelin announc think timelin impact brexit
discuss potenti elect
provid thought earn call referenc high
singl digit revenu growth ebitda margin improv suggest ebitda
would grow high singl digit possibl even low doubl digit would character
comment relat consolid sinc plan exit
uk busi would better think comment relat primarili
earn call last week compani mention sever compon would
contribut busi outlook cite turnaround facil
oper challeng cost save program bed addit facil expans
seem suggest high singl digit revenu growth figur rel
updat guidanc howev compani also mention talk
expect growth base normal year recoveri oper issu
could drive growth higher base two comment infer expect
revenu growth normal year mid-singl digit growth higher
normal high singl digit delta turnaround specif
think compani come year
expect three quarter report novemb
surpris play expect
better wors
nurs alli
coupl week ago report solid result exceed street expect
still see strong growth alli solid growth travel nurs
give us flavor differ sub-seg nurse/ busi
perform quarter broadli perform evolv past
year two
compani guid nurse/ organ revenu growth flat
that littl surpris given strong growth saw competitor mention
order flow come bit slow winter month suggest may
order volum rel prior year see someth
similar reason organ growth expect flattish
particular nurs specialti crna psychiatr nurs etc see
higher demand right
advanc medic perform sinc complet deal earlier
would expect point particular challeng
locum busi challeng period work
system chang y/i comp perspect final lap quarter
revenu sort re-baselin lower level give us sens see
growth trajectori locum busi move forward top line begin grow
base produc head count today sort capac
locum busi revenu growth would need start ad increment
head count
margin locum busi key lever improv
margin view trajectori
type specialti within locum univers in-demand right
find difficult recruit candid
manag servic program workforc solut
year ago announc renew kaiser msp expans
msp addit market obvious disclos kaiser largest custom
could provid color extens expans go one year
percentag revenu come msp increas significantli recent
year new space describ msp work
differ tradit staf relationship msp valu
penetr msp healthcar staf today still runway new msp
think futur win come take share
anyth uniqu certain hospit make suitabl msp
relationship msp common smaller larger hospit certain
averag size msp contract today see growth
busi particularli larger smaller contract
averag term msp contract long take ramp msp
contract ramp period reach fulli implement
program usual signific up-front start-up invest
asid msp see greatest opportun outsid
think impact econom downturn
diversifi broader workforc solut compani includ msp
baselin busi
updat us thought regard normal organ growth rate across
three segment nurs alli solut locum tenen solut workforc
drill specif area within segment
fastest grower weakest grower even declin point
focus term would rank prioriti
pipelin look like right
within past year weve seen major public peer hire new ceo work
turn compani trajectori around separ weve seen two rel larg
player privat market combin creat probabl fourth largest
healthcar staf compani market major player travel nurs
alli comment around develop impact
competit environ speak broadli state competit
environ healthcar staf
see neg impact continu shift lower cost outpati set
rather inpati set target initi ensur
staf provid choic outpati set well current presenc
offer outpati set today
three-quart way thing
gone better expect year
challeng rel year began full year rais
along call want comment drove chang
felicia join two year ago run govern busi
attract expect realiz
unexpect opportun come unexpect challeng
govern segment margin declin bp y/i declin
bp y/i increas bp y/i drove
y/i improv trend
level set everyon medicaid busi call under-perform
expect sever confer call year sound like compani
origin guidanc contempl roughli pre-tax margin busi year
run closer right would describ princip driver
varianc
compani said seek rate adjust number state level
activ seem higher normal give-and-tak state right
abl lock discuss on-going
seem one hand issu get rate increas appropri
also commentari oper effici antm
medicaid busi could improv right improv
cost structur medicaid busi
iowa medicaid program challeng three initi mco servic
contract fact two compet plan left market point
hung other compani perform state
satisfactori level view
biggest problem recent year mco medicaid seem occur state
goe fulli ff manag case iowa north carolina roll
similar full convers program well next year confid
wont issu roll-out iowa
talk bln worth increment busi opportun
medicaid end new busi shift
manag care includ re-procur incumb hope
gain share give us flavor
lot discuss opportun convert high cost live medicaid
dual ltss etc manag care percept convers live
manag care taken longer peopl expect year ago agre
taken longer
texa star plu award recent announc presenc reduc
five region eight current depend live divvi estim
could repres mln annual premium headwind sound right
protest award believ protest due earli week
think chip rfp given result plu
work sever plan launch partnership go medicaid
busi one place go addit one
compani put high prioriti grow busi next year
seem like first prioriti upgrad product offer key blue market
process rel complet satisfi offer
said among thing stand ingeniorx help make
competit medicar part comment import get
pbm run product offer fulli reflect
benefit ingenio improv
antm enrol ytd put track within
growth outlook year nearli growth compani suggest
grow busi mid-teen growth rate next number year still
nearli month medicar advantag think
enrol expect sever peer report
recent state expect growth overal market growth
said disappoint rate outcom releas week
ago result impact compani think growth
specif percentag live expect plan
believ compani rate impact clinic pharmaci score
posit group opportun remain larg untap
compani especi given strong commerci aso busi compani
said expect see continu growth group expand
bit remind us mani live expect end year group
believ around also share thought opportun
busi long-term compani still expect live segment
next year
balanc sheet capit deploy
think capit avail end
d/c ratio roughli bln cash cash equival invest
parent compani remind us compani lt d/c target
lt target alloc roughli free cash flow share repurchas
ytd compani run roughli assum good run rate
capital-expenditure given compani expect bln share buy-back
year would impli alloc roughli free cash flow
share repurchas higher target function market pullback mco gener
particular
compani prioriti futur point
movement insur forward integr least
doctor group florida medicar advantag acquisit caremor
subsidiari integr model talk step take
build provid specialti platform much prioriti thing
want confirm understand comment compani made
preliminari outlook take benefit ingenio year year
core earn least wed grow base
low end growth rate would give us core earn
would add full ingeniorx benefit arriv
move part math consid
make sure think correctli build-up basic
assumpt typic articul today
individu market drop high-end long-term target rang
medicaid margin rise low end target rang name
consist y/i hif continu pass-through commerci
medicaid book absorb medicar still yield margin rang
book ingeniorx deliv mln save cours
gener correct anyth els highlight put take
compani said sever time call ingeniorx fulli run
competit price product peopl hear competit price sometim
get concern compani talk discount market
mean competit price market least pbm
servic come line impli sens may
upsid bln save number
 util trend expect
continu expect medic cost trend rang believ
point usual provid bia within rang whether expect
midpoint reaffirm rang impli bia near
midpoint given compani outlook bias toward upper half
start guidanc would assum bias upper half cost
bp higher consensu bp y/i year
compani attribut y/i gain hif last quarter medicaid mention
pressur point year first trend rel compani
expect imbed guidanc varianc due neg associ
commerci contract termin mention extra busi day
meaning drag
full year outlook impli bp
increas y/i given rang wide walk put
take might move within rang believ hif
bp drag less due comml time issu
individu enrol declin sequenti public exchang
chang expect around margin trend individu book vs
compani said previous continu enjoy trend long-term
individu busi pressur number year bright spot
margin book come high end
target margin rang happen exchange/individu market price
final gotten accept level extent driven fact peopl
histor abl get coverag coverag sever year
issu relat pent-up demand play point
along line compani said assum return normal
exchang margin next year preliminari comment outlook
driven return increment competitor individu market next year
simpli rate price increas segment moder
grow specialti program membership prioriti last
year half progress initi much runway
think long-term compani said would like close profit gap
aso member fulli insur member
progress goal target could achiev
updat time otherwis respect cigna/esrx litig
think compani come year
expect three quarter report novemb
surpris play expect
better wors
nurs alli
last week report result exceed street expect give us
flavor differ sub-seg nurse/ busi perform
quarter broadli perform past year two
mention order flow come bit slow winter month
suggest may order volum rel prior year
give us color order trend see reason
point order may come bit slower
expect around flu season tighter manag agenc labor specif larger
custom someth els
particular nurs specialti crna psychiatr nurs etc see
higher demand right need particular need particularli
difficult fill
outlook physician staf segment point complet
bottom think growth trajectori move forward
need make happen
key lever improv margin view trajectori
type specialti within physician staf univers in-demand
right find difficult recruit candid
talk msp strategi msp win year-to-d much spend
ramp
much revenu come msp point
describ msp work differ tradit staf
relationship valu proposit offer msp
penetr msp healthcar staf today still lot runway new
msp think futur win come take share
anyth uniqu certain hospit make less like want msp
relationship msp common smaller larger hospit certain
averag size msp contract today see growth
busi particularli larger smaller contract
averag term msp contract long take ramp msp
contract ramp period reach fulli implement
broad workforc solut opportun pursu asid msp
baselin busi
updat us think normal organ growth level across
three segment
drill specif area within segment
fastest grower weakest grower even declin point
focus term would rank prioriti
pipelin look like right
recent saw two rel larg player privat market combin creat
probabl fourth largest healthcar staf compani market major player
travel nurs alli comment around could chang
competit environ speak broadli state
competit environ healthcar staf
see neg impact continu shift lower cost outpati set
rather inpati set target initi ensur
staf provid choic outpati set well current presenc
offer outpati set today
talk recent earn call mln expect realiz
cost save program mln anyth addit plan
go cost follow complet cost save program key
area cost save program focus
three-quart way thing
gone better expect year
challeng rel year began
call point start point compani ep outlook
last year compani highlight consensu time
within guidanc rang compani provid initi rang
decemb essenti bracket consensu number point sever
week prior call ceo michael neidorf point outlook
comment conserv start point fair assum compani
like bracket /- rang like last year point make
might go higher potenti midpoint
previous said expect grow hix enrol stabl hix margin
y/i local region competitor market expand
re-ent expect margin pressur membership churn market
off-set gain new market counti y/i stabl margin comment refer
point estim compani continu expect within margin
think hif impact use bp
figur increas given cnc grow busi
mention hif repres roughli impact tax rate use
effect tax rate outlook base mean compani guid
tax rate
risk adjust payabl mln end fair say
like assum roughli favor true-up benefit risk
adjust program accrual similar approach compani head
cnc came bp y/i includ mln
california medicaid in-hom support servic ihss program premium
bp bp relat hif bap relat at-risk state direct payment
california bp relat wed like dig categori
would assum includ hix normal fide deal iowa
medicaid mayb pars talk categori impact
compani say call saw meaning improv revenu
medic cost line fide talk much benefit compani saw
fide y/i y/i comp extra monday septemb
impact y/i
maintain full year outlook impli
would assum given increas hix retent would
sequenti increas even exclud bp at-risk ca payment
would take either toward high end outlook
explain put take your consid
think given higher hix retent sinc hix busi
break-even slightli profit much drag compani anticip
hix rel past year hix medicaid trend
base roll-forward tabl provid calcul gross prior year
develop mln compar mln understand compani
focus consist prior period develop net
expect maintain hix membership histor
compani believ higher level retent would sustain membership
end compani expect
give confid grow hix enrol
headwind think rel pre-tax target margin
margin normal compani still believ margin
still level y/i assum bln hix revenu
still good figur
local region competitor market expand re-ent
expect margin pressur membership churn market
off-set gain new markets/counti
success reprocur region procur new region texa
star plu rfp sens live divvi new
round contract abl keep live current enrolle
activ enrol live split evenli amongst new player per region
follow success reprocur think texa
chip rfp award still track dec releas
elig redetermin true-up state receiv payment
true-up intra-year happen begin year receiv
payment true-up sinc last year point elig re-determin
california washington given year sinc last mention
seen relief state yet
respect iowa medicaid contract assum would market share
assum fair share ltss live well live year end mani live
add iowa think goal still achiev
success gain addit region region north carolina
announc award end protest still tri get statewid
contract given on-going budget stalem north carolina seem like launch
contract might delay juli anticip feb start date
insight
indiana recent issu hoosier connect rfp abd popul propos
due jan current market share roughli live
remind us perform contract
report new york state may cut bln next five month
medicaid address health care cost overrun given fide exposur state
color provid go state
point medicaid flat y/i basi improv
network medic manag initi off-set effect membership
reduct elig redetermin flat medicaid comment includ
iowa new mexico pennsylvania ltss way break much
basi point impact network medic manag initi y/i
talk medicar advantag posit believ compani
plan exit new york counti fide expand counti exist state
add one new state nevada well begin ascens jv four geographi
kind growth see busi remind
respect margin target expect expect y/i margin
improv
octob publish updat medicar qualiti rate rate
year cnc medicar member star plan bonu
year compar bonu year cnc qualiti bonu rebat may
neg impact unabl util mitig strategi mitig
cnc/wcg announc divestitur wcg missouri nebraska plan
part deal divestitur expect announc
approv state made approv conting divestitur believ
wait illinoi new jersey approv discuss state
gone led take longer approv state
compani highlight expect revenu lower sequenti result
state-direct payment report premium bln exclud
payment premium would bln compani anticip
similar level premium revenu adjust figur
last updat provid rxadvanc success migrat six
state repres mln live rxadvanc platform migrat addit
state compani look medicaid exchang state
platform end medicar end recent made
increment invest rxadvanc walgreen explain partnership
walgreen mean
three-quart way thing
gone better expect year challeng
rel year began
beat consensu expect guidanc rais
suggest out-performance rel ci expect rel
intern expect came better quarter
point compani usual provid updat bia medic cost trend
sound like reaffirm full rang suggest
midpoint remain like outcom compon cost trend perform
better wors
look like earli vantag point guid
exclud pyd share repurchas compani talk take midpoint
ep outlook remov prior year reserv develop
absenc tax matter resolv return hif told three
item amount bring baselin compani expect grow
organ capit deploy captur synergi effect
de-lever baselin put take take low end
high end key tailwind headwind
keep mind contempl
think hif impact believ compani size
bp prior year thing compani done off-set
impact hif
manag said health servic perform better expect
also said segment singl digit y/i apples-to-
appl basi expect pattern flip sound like compani
mid-singl digit growth mid-high singl digit full
major driver gotten compani posit y/i segment
track achiev roughli mln synergi deal segment
updat outlook divis assum bp core growth slight
narrow rang vs previous
talk perform accredo busi expect
time merger express script believ esrx commerci
book alreadi penetr roughli esrx health plan client use accredo
steadi penetr rate legaci esrx grow begun cross
sell accredo legaci client base big revenu earn
opportun cross-sel opportun
beyond accredo updat us cross-sel initi
servic integr medic understand synergi guidanc
origin includ revenu synergi thought big revenu synergi might
time
implement cost relat deal incur year go
away next year think impact busi
said releas bp y/i increas driven hif
price impact higher individu commerci busi extra busi
day compani benefit inclus pdp result
busi tend lower vs
individu book higher origin expect
compani expect land respect hix margin last year compani point
moder individu busi margin expect mln after-
tax headwind occur
talk commerci health busi sell season coupl year
market growth nation account segment enrol book
pressur year y/i ytd color
growth select segment membership ytd continu outpac middl
market growth ytd color enrol trend compani
highlight last quarter littl lower perform upper end middl market
portfolio part market becom competit
compani mention nation account high end market
client typic less penetr specialti servic explain
ci offer hix product state arizona colorado illinoi missouri north
carolina tennesse virginia state az
expand hix offer three state kansa utah florida
well new counti tennesse virginia total market
compar expect pick-up hix enrol
compar step-down seen cigna expect individu
busi margin moder
grow medicar remain high prioriti compani provid lt
membership growth assumpt expect least growth
talk littl bit compani reposit
acceler growth next year
grant compani start smaller base peer still solid
like market growth much growth come new market
new product ci offer ppo-styl product versu legaci markets/product
histor cigna busi portion heavili tie doctor collabor
risk share busi tie tradit fee base relationship
provid growth expect go skew toward one type provid
overal govern busi remind us pre-tax margin
target respect expect
compani view medicaid market junctur recent
unsuccess re-procur texa medicaid contract contract rel small
grand scheme thing mln revenu less ep
impact given implement date sept outcom
indic anyth respect compani focu medicaid go forward
seem like state bit slower roll valu ad program
ci interest market hope agre
revenu grew y/i currenc adjust basi latest quarter
describ peopl may new stori growth come
intern portfolio highlight recent trend largest
group disabl
group disabl segment y/i first nine month
year compani need achiev lt earn growth target
extent revenu busi deriv via cross-sel health plan
risk aso client
earli septemb press report new coverag program call embarc
benefit protect expens gene therapi highlight
coverag luxturna inherit retin diseas zolgensma children
spinal muscular atrophi mln launch understand
compani hasnt set fee yet articl point aim less
pmpm program work minim risk
deploy million repay debt bln bln
repurchas million share stock million
mln mln increas repurchas lower debt repay
function market condit recent perform manag care stock
alreadi exceed goal bln share repurchas year expect
deploy bln share repurchas boost share repurchas activ function
better expect cash flow year acceler share repurchas vi -- vi
debt paydown impli someth pull-forward buy-back activ
three-quart way thing
gone better expect year
challeng rel year began
think retail/ltc segment specif market evolv
significantli compani pursu number initi includ healthi
program segment industri larg look differ next
three five year
front end store experi greatest chang pharmaci
expect see signific capac come segment one point
compani spoke new store addit potenti
compani expect add net store count modestli forese futur even
industri gradual contract
ss retail/ltc adjust prescript growth vs
would seem better overal market agre pace
growth compar intern expect come year
launch number initi last year clinic care program like
prescript program includ mainten choic adher program
enhanc network relationship program drive script growth versu
consum experi versu profit busi know object inter-
relat get one object other
highlight improv perform long term omnicar driver
retail/ltc out-performance specif gotten better unit
pharmaci benefit landscap chang significantli last two year
biggest independ pbm esrx purchas health insur one
largest insur decid stand pbm help
purchas health insur step back quarter quarter
put take think develop chang competit
landscap pharmaci benefit manag react chang
term competit posit
seem higher usual volum busi renew
launch year pbm sell season agre case
start date compani express optim
consider public polici scrutini issu consum pocket
cost particularli relat drug cost administr ultim back
drug rebat reform propos medicar part still seem consider
interest congress someth assess landscap regard
issu benefit design chang pursu caremark
aetna allevi out-of-pocket cost consum caught exampl high
comment innov thing consid way address
issu high cost specialti drug make access patient need
also keep cost manag exampl earli septemb press
report new coverag program expens gene therapi
highlight say plan offer new layer coverag specif gene therapi
would handl self-insur employ cost certain threshold believ
program cover luxturna inherit retin diseas zolgensma children
spinal muscular atrophi expect avail stop-loss
program seen much uptak employ mitig risk back
articl also point work broader reinsur product
understand specialti revenu repres total pss revenu
area consist growth dispens specialti revenu increas y/i
vs last year compani purchas specialti
busi premier think one-off acquisit would compani
look acquir asset area would compani hope accomplish
acquisit specialti
own aetna better part year surpris
unexpect challeng
think segment within benefit segment medicar advantag
bright spot year busi post one strongest enrol
year record clearli nearli enrol growth driven part
geograph expans part broaden compani product offer exist
market well underli high singl digit growth market assess
compani still runway expand geograph respect
product offer like see growth moder still solid underli
lot discuss return health insur fee
like impact industri compani enrol growth thought
cvs/aetna manag trade-off maintain benefit maintain profit
hold onto grow enrol return hif creat
commerci market seemingli rel steadi howev compani
experienc pressur middl market commerci busi live
sound like specif geograph market compani talk
implement clinic medic manag initi deal issu
work headwind like continu
medicaid busi posit announc year
challeng award contract cover florida healthi
success secur contract enter texa star plu program contract
look like could repres bln annual rev altern compani
incumb louisiana award new contract award made
summer would assess state aetna medicaid busi
thought see nice success certain market challeng
outcom other busi becom competit state focus
capabl aetna need work updat kansa medicaid
contract believ manag chang follow back forth
state
compani guid medic cost increas year rang
stay place year compon cost trend meaning
varianc begin year
recent announc regard settlement pend opioid
case view respect issu
compani rais expect sever time cours year
current guidanc rang investor day june
compani point least ep also talk low-singl
digit earn growth think headwinds/tailwind headwind
pyd mln sale part busi wcg roughli mln
earn loss louisiana medicaid contract carve-in cnc pbm busi
tailwind enrol growth commerci matur
see greater profit hif return tailwind pre-tax earn
synergi improv aet transact mln mln
origin mln miss anyth ytd out-performance
chang think respect
think compani come year
expect three quarter report novemb
surpris play expect
better wors
state overal industri today oper reit arriv
reason place financi structur reason leas term
els chang industri recent year good reason optim
futur snf industri
medpac data suggest number snf declin slightli
number facil roughli flat number year
that probabl help industri occup level weak recent year
age popul suggest point could need increment
capac view capac industri right vs
think capac need start rise end
increas number facil end larger facil bed
medicaid patient day mix continu increas meaning time almost one
enter facil use medicaid reimburs primari payer rather age
medicar privat benefit exhaust still case chang
grow medicaid censu posit boost occup could becom
neg squeez profit resid
obvious state realli challeng medicaid rate like texa youv
exit compani emphas reorient portfolio back larg
east mississippi gener posit state east mississippi
compani call uptick wage rate trend recent quarter
see think function strong economi someth els
mitig strategi employ wage increas plan
medicaid rate increas look kind visibl right
larg state genesi slow final rate
see meaning trend manag medicaid impact busi
penetr reach level satur
anyon hasnt follow close give us brief overview patient-
driven payment model pdpm mean genesi industri
youv seem fairli bullish outlook genesi pdpm impact
payment rate posit provid neg other understand
cost opportun well talk top-lin impact
anticip cost save gener
youv talk cost save achiev group therapi new
system weve seen press report suggest snf genesi particular
termin larg portion therapi staff octob suggest
patient care decis made base reimburs opportun could
address staf chang made sinc pdpm went effect
made chang
separ medicar reimburs topic garner interest recent
potenti shift unifi post-acut payment system medpac work
model congress requir look think potenti
impact unifi post-acut payment system see snf industri overal
net winner net loser genesi specif
give us color exist powerback rehab facil
meaning contribut point much develop
opportun see move forward look
opportun near-term
recent done coupl interest deal youv gotten ownership
interest real estat receiv right buy rest ownership real
estat futur talk strategi around one key
strategi look make sure busi end move
stronger sustain direct
press releas mention facil locat histor
eastern market give us sens geograph footprint point
expect go time complet done portfolio
addit facil exit much portfolio optim left
qualiti metric track think import use includ
qualiti metric compani perform vs peer metric
think compani come year
expect three quarter report novemb
surpris play expect
better wors
volum price trend
said long run adjust admiss like
facil basi oper fast grow urban market across countri
target assum properti experi volum growth similar
underli market trend requir market share gain factor
could allow outperform object
volum help compani focu ad access point
freestand er health clinic outpati surgeri center etc judg
success invest need gener return stand-alone
basi abl factor irr help give rest busi
tri extend reach import compani extend reach
non-urban set smaller commun market
volum acceler sequenti admit vs
equival admit vs inpati surgeri vs
outpati surgeri vs much
would attribut extra monday septemb particularli relat surgeri
oppos gener strengthen market
ceo hazen said recent market data show share gain bp
all-tim high see greatest gain market share
geograph particular servic line
host new york septemb discuss
market physician-rel issu pressur ss surgeri
improvement/resolut issu besid extra busi day
reason surgeri growth improv sequenti
outpati surgeri center volum flat modestli base commentari
earn call trend occur recent quarter
uniqu growth surgeri center modest compar outpati
surgeri trend hospit campu
mention total joint surgeri volum grew trend
see time new drive strength demograph
capit invest physician recruit see strength orthoped
across board specif total joint
hear lot rise consumer healthcar fuel part prolifer
high deduct health plan impact respond
trend
see term shift valu base payment extent
qualiti becom compon reimburs structur either commerci
govern payer see qualiti becom greater differenti factor among
competitor futur gener comment amount busi
recontract manag care beyond
call improv ss margin bp due
tighten cost respons result would say normal
cours cost line item drive posit y/i swing
comment competit physician find still
consider interest employ hospit effort simpli
recruit doctor refer physician staff becom less competit
labor product metric seem strong agenc labor util trend
bought nurs school last year happen move
needl labor expens line time impact way
comment suppli expens trend see increment success
area healthtrust hpg success get healthcar system
umbrella discuss opportun see hpg
opportun signific way market hpg non-profit system
overal result outlook
lay think core growth end much
recent acquisit contribut your expect
expect meaning margin improv recent acquisit
hospit top line perform deal grow rev faster core
initi take hold
think leverag point remind us target
comfort today
term acquisit pipelin see mission health
savannah deal gener inquiri system
buy-back activ overal lower recent year
chang way compani priorit share repurchas within context overal
capit deploy expect move beyond
number topic political/legislative/regulatori sphere right
includ medicar price transpar surpris bill legal challeng
dsh cut see import focu oppos polit nois
see issu major threat industri
feder american hospit focus lobbi effort
think compani come year
expect three quarter report novemb
surpris play expect
better wors
busi overview competit environ
provid brief overview busi model valu proposit
custom choos busi custom
altern busi much save averag
custom realiz busi save achiev
dont larg scale direct competitor smaller market
see competit insourc vs
compani provid similar outsourc servic stadium
hospit particular reason compani would tri enter snf
dining/nutrit housekeep market compet one
compani tri compet would advantag
talk plan expand busi alf senior live
facil mention past thought movement
toward would meaning competitor area
past year compani announc signific restructur
elimin custom contract talk bit situat
occur much activ occur rel short period time
much type activ might still horizon
flow solid year remind us think cash
flow on-going basi think roughli equival net
talk current gross margin target path/vis toward
achiev recent quarter seem like would without
extra cost payrol cost legal cost etc actual reach level
expect dietari margin reach similar level housekeep margin time
long think could take
see top-lin growth trend across two busi line long-term
investor think revenu growth modest busi add
sequenti quarter lower histor growth level
updat us strength overal custom base snf industri
larg hear today custom regard patient-driven
payment model prepar transit adjust smoothli
interest dynam gate factor growth alway
manag pipelin quickli take busi recent
earn call talk custom work transit pdpm
slow rate add new busi long think
dynam last
good see new busi addit expect new busi
addit reacceler normal level phenomenon could occur
first quarter look someth like late earli
snf time adjust new reimburs system
think compani begin year
expect three quarter report
novemb surpris play
expect better wors
stephen nearli year surpris
come place opportun greater thought
place challeng greater thought
oper trend organ growth
area busi see fastest organ growth vs slowest
deliveri across hospit cover see strength
weak particular geograph market broad-bas
long-term outlook respect birth trend perspect
particular reason seen strength recent
compani mention anesthesia volum growth strongest servic
line consist trend new phenomenon third
compani call mid-singl revenu growth radiolog pretti typic
run trend
long-term outlook same-unit price growth md key segment
compani mention earn call mani manag care contract
evergreen vari servic line still sort reimburs rate
inflat built contract work
past year two weve seen neg payer mix trend particularli around
anesthesiolog busi caus shift neg shift begun
moder point annual view mix shift complet
relat demograph peopl age medicar
compani overal margin pressur last two year
busi challeng term margin pressur
youv talk cross-sel opportun remind us
see opportun front
radiolog practic group focus sole five market your
florida texa tennesse new england nevada look expand
geograph well
updat us anesthesia contract rework
much expect next year
origin got radiolog busi vrad past year md
acquir facility-bas practic updat us practic
well integr vrad
opportun see uniqu take advantag
two type radiolog busi one corpor umbrella
comment call regard bp margin pressur
would see margin headwind declin think
model guidanc suggest margin declin someth
like bp less could margin flat y/i
expect acquisit activ re-acceler rel better
think steady-st y/i basi pipelin look
main acquisit prioriti
radiolog deal multipl similar neonatolog deal multipl bit
higher also talk multipl synerg basi nomin
basi much typic abl reduc effect multipl time
long typic take
look acquisit see teamhealth envis market
much clearli much highli lever keep
market case
leverag still view debt reduct major capit prioriti
point would weigh share repurchas acquisit increment invest
transform program heavili
cfo stephen farber mention mln cash tax benefit meddata deal
obvious also got mln cash front well there also potenti
mln conting consider time period potenti realiz conting
consider final much transact fee pretti much
off-set cash tax benefit
think compani come year
expect three quarter report novemb
surpris play expect
better wors
ltach industri went challeng period year ago signific
reimburs chang patient criteria past coupl year though
busi seem stabil improv volum improv occup
level set us ltach busi stand today strategi help
succeed reimburs chang see outlook
industri select specif
level growth reason ltach segment select drive
compet ltach market much crossov kindr
geograph sem ltach usual ltach market
medicar reimburs landscap look like ltach near-
intermediate-term occasion discuss exampl normal payment
across post-acut segment seem subsid want get
panama citi ltach facil hit hurrican littl back
updat us situat drag seen facil
expect see move forward
payment rate vari across differ payor opportun grow
non-government portion busi segment updat us
price differenti medicar ff medicar advantag ltach
inpati rehab rel hot area consolid select
encompass kindr invest fairli heavili space select particular
ad facil year see solid demand growth market
whole think select gain share industri capac growth
compar demand
see sem competit advantag vs peer space
one major peer irf space talk lot focu target stroke
neurolog patient grow share area similar focu
particular condit select irf known handl well
target irf develop mani plan roll near term
long term annual basi remind us
pipelin right irf develop partnership
weigh opportun open wholli own rehab hospit vs partner
acut care hospit form joint ventur strong prefer
joint ventur model benefit see joint ventur model oppos
wholli own model look potenti jv partner
typic ownership structur acut care hospit
jv push particular ownership structur depend
needs/desir acut care hospit partner
much develop cost start-up irf fund pro rata
jv partner base ownership percentag typic ownership percentag
jv partner timelin
organ growth profil irf growth profil improv
meaning great acut care partner
payment rate vari across differ payor updat us price
differenti medicar ff medicar advantag irf busi
california market california rehab institut import part rehab
hospit busi updat us perform outlook move
concentra nice growth trajectori sinc acquir
ad us healthwork segment februari driven addit
growth nice synergi view growth strategi move forward
addit deal done add segment view normal
organ growth segment
particular target develop occup health center much
develop new occup health center typic cost long
earli next year jv partner concentra opportun put
ownership interest select assum ownership interest get put
select plan financ purchas one-third partner concentra
interest believ arrang partner would allow stock use
lieu cash chose go rout like anticip fund
cash flow and/or debt
put option continu februari one-third increment year
time get select would option buy back full ownership interest
elect hasnt put back compani expect
time get end first quarter select concentra
given meaning amount cash may spend buy
ownership interest next year spend segment
describ growth profil growth strategi outpati rehab
ad new clinic prioriti compani pursu overal growth
on-go prune portfolio well much develop new outpati
rehab clinic center typic cost long take
see tuck-in acquisit opportun busi line kind
multipl would pay major acquisit could pipelin
particular leverag target organ
thought around share repurchas
see labor cost trend variou busi rehab
hear reimburs chang skill nurs eas
supply/demand tight therapist agre
think compani come year
expect three quarter report novemb
surpris play expect
better wors
compani properti divers urban market across countri tenet
spent sever year restructur acut care portfolio think
hospit portfolio point compani number one number two
continu market gener percentag facil market grow
faster nation averag portfolio restructur larg done point
on-go opportun redeploy capit
volum trend steadili strengthen compani past year
obvious relat portfolio prune like relat overal
industri strength relat initi perhap
manag chang divis last year think driven
improv volum point view outlook volum growth
move forward long-term basi
discuss see respect manag care contract
notabl chang expect payment rate term contract
percentag tenet manag care contract lock
hear lot value-bas payment see increas
percentag payment tie behavior
seem rel benign govern payment environ junctur
supplement payment one sourc volatil expect all-in
medicar inpati outpati price medicaid averag across
state
manag care front payer continu tri forc certain procedur
outpati set requir preapprov procedur etc recent made
announc would requir addit procedur done non-
hospit set start novemb see meaning initi
acceler shift volum new set near- intermedi term
see normal cours
asid asc thc non-hospit footprint like term freestand
emerg center urgent care center diagnost imag center etc much
growth focu site servic
volum revenu quit strong uspi year ss volum growth
ytd ss revenu growth see
sustain rate growth someth unusu year
talk acuiti payer mix trend busi particular
servic line grow faster other busi anticip
growth medicar popul headwind price come year
would describ competit landscap deal busi
strong pipelin acquisit vers develop opportun look
 segment type multipl see
term competit environ much market overlap
major consolid asc competit differ exampl
move payer market recent year disrupt thing way
drive acceler y/i margin expans conif segment
past quarter much still come conif margin
margin gain steadi conif recent period top line growth
hard come think see reacceler top line growth near
intermedi term need propos spin-off complet perhap
new ceo get place season pattern sell season conif
busi lead new custom win occur particular quarter year
updat conif spin-off process partner conif commonspirit
formerli digniti activ involv process point
indic plan respect equiti stake everyth els go accord
offer color major cost reduct initi compani
undertaken past year focus
accomplish focu cost save direct go forward
see term labor cost wage still increas rang
comment see respect nurs turnov and/or use
temporari contract labor overtim
mln guidanc rang ebitda seem pretti wide major swing
factor tenet tri account
consolid ebitda margin expand y/i bp howev look
like guid midpoint consolid ebitda margin declin
bp anyth call y/i basi drive swing
break-out quantifi factor contribut asp pressur fx vs mix
shift updat think asp trend longer term
speak new consum orient market activ strategi
tv vs on-line vs print teen vs adult exactli campaign start
success consumer-ori market campaign to-dat
measur success newer market effort expect elev
level market spend continu longer term
term doctor-ori effort promot leverag
directli price concess bundl co-market
broader macro perspect speak sensit across busi
potenti volatil macro environ
think season across domest vs variou intern market
growth china meaning better anticip
expect support elev growth china longer term longer term growth outlook
growth target dwarf lst peer coverag univers
help us get comfort lt outlook light growth retreat
lower end guid past sever quarter conservative/achiev
lt target key underli driver
think margin trajectori next sever quarter
ramp new china manufactur facil variou treatment plan facil
salesforc invest litig expens anticip
think longer term oper margin target
restructur effort better posit lt tax advantag
youv highlight past relationship aspen dental heartland dental
speak dso strategi would character discuss
give us updat third-parti financ initi econom behind
offer key growth driver longer term traction
updat develop pipelin hole still look fill
palat expand focus develop product ortho
think spend come quarter longer term
capit deploy prioriti philosophi type asset might make sens
larg deal would compani consid
speak doctor-l invisalign experi locat mani locat
current econom work traction
non-compet end establish direct consum clear align compani
expect open own invisalign store similar previou
strategi
sever industri constitu launch clear align offer us
other reaction new entrant provid updat
competit environ evolv sinc launch new offer
straumman clearcorrect product compar invisalign
think potenti impact launch market intern
import recently/ upcom patent expiri limit competitor particip
market vs extent barrier entri driven deep market
penetr market capabl
think threat competit direct consum clear align
busi quantifi overlap
sinc began ship mandibular advanc us long
take contribut meaning result roll-out typic look like
type newli launch product
speak notabl slowdown volum growth north america past
coupl quarter view key driver new normal
traction invisalign first feedback thu far
roll-out brazil broader traction market opportun
traction see smile concierg servic launch last year
speak opportun retail concept walgreen
rate would expect grow number new doctor balanc
year would estim current penetr potenti doctor us vs
region
ad new doctor long typic take see meaning case volum
ramp similar averag level product rule appli
doctor prescrib case
sustain rapid growth china driver across geographi
updat approval/launch palat expand
experienc growth itero revenu follow
break driver itero growth expect growth trend
remaind year beyond
speak relationship glidewel dental overal distribut
strategi itero
receiv china fda approv sell itero element china speak
china strategi penetr trend relat itero scanner
opportun exist market
updat global distribut agreement itero element zimmer biomet
timing/magnitude/feedback associ launch new itero cari screen
intern updat time us approv
anticip meaning declin pharma profit -hsd dd
pars driver expect profit experi magnitud
driver think expect return profit growth core pharma
speak recent contract renew notabl chang
contract consid price line expect remind us
red oak relationship renew come due
speak gener deflat environ would character stabl
extent gener deflat headwind profit growth
would character steadi state rate gener deflat regulatori
barrier fda backlog approv influenc buy side price dynam
would say high single-digit even low double-digit deflat sustain
enough manufactur drop market rate
opportun see leverag red oak sourc jv
way add valu strateg partner besid gener
impli guidanc term overal specialti growth guidanc
assum meaning contribut biosimilar continu view biosimilar
opportun longer term
speak exposur brand drug price inflat implic lower
expect inflat environ model expect
on-going move away contract depend drug price inflat
essenti compon overal compens give us idea split
overal gross profit gener drug distribut come fix contract
versu variabl expect mix evolv go forward
think risk factor well opportun relat new
drug import propos think cardin posit regulatori
forecast lsd top-line growth medic segment
think longer term growth profil segment go forward
speak factor impact medic segment profit quarter
make feel comfort posit profit trend quarterli
season factor dynam consid
youv recent announc conduct full strateg review portfolio
provid updat thought medic busi commit
weve seen close competitor medical-surg distribut space recent face
signific pressur speak underli medic distribut growth
competit posit market
youv spoken previous commod pressur impact medic segment margin
past headwind tailwind recent quarter help us
think exposur commod pressur also step take
order mitig pressur go forward long current spot rate
typic take roll
speak charg took relat exclus distribut
agreement supplier expect similar relat charg futur
see falloff servic level exit patient recovery-rel tsa
someth plan someth particularli
surpris note known
youv mention servic level improv new initi long
take see full recoveri busi setback spill
talk cordi initi pat holt new head cordi jon giacomin
medic segment ceo type chang expect much
progress made thu far help us understand trajectori toward
profit growth end lt vision
provid updat continu suppli disrupt exam glove
expect subsid speak fundament demand trend key driver
across medic busi
divest major interest navihealth pe firm speak strateg
rational behind transact increas invest sort growth
view navihealth achiev longer term divest perceiv
provid updat progress relat search perman
cfo choos appoint interim cfo extern
speak target million gross cost save much
low hang fruit provid exampl help us think initi
entail much cost save reinvest much actual flow
cadenc
provid updat progress toward broader opioid-rel settlement
follow recent two counti settlement ohio
recent news potenti opioid settlement think capit
deploy made chang capit deploy strategi light
provid updat debt pay leverag ratio go forward time
share repurchas
think foreign currenc exposur
provid updat opioid relat headwind associ
costs/expens progress compar expect surpris
provid us view potenti impact jpm/amzn/brk ventur
busi industri gener also implic medic
thought amazon step drug suppli distribut servic chain
acquisit pillpack last year
thought around potenti impact medicar legisl drug distribut
give us updat underli demand trend amongst biopharma
could provid updat biotech fund environ healthy/on pace
balanc sheet
fundament demand differ across mid-siz biotech versu larg pharma
point differ significantli across differ earli stage function
discoveri safeti assess dsa
view trajectori discoveri long term describ on-going
pace progress far get better custom pull discoveri
safeti assess goal current certain custom type
inclin
provid color busi mix citoxlab fit
safeti assess discoveri busi kind custom overlap
citoxlab synergi opportun
experienc bp margin headwind relat citoxlab acquisit cost
put integr citoxlab relat previou expect
quickli think rais citoxlab op profit margin mid-teen
pace de-lever par expect
could give us updat wil perform mpi
kind util anticip new site south san francisco
particularli cradl initi expand cost estim
account cradl expans
rm supply/demand dynam look like recent research
model longer term expect perform
provid updat competit dynam within china competit
advantag leverag grow busi
think margin impact lap niaid contract
emerg competitor china rm see growth dynam
biolog could speak competit dynam specif space
long term growth opportun expect pa facil full
oper know microbi busi less capit capacity-intens
kind invest make area
volatil manufactur profit margin past quarter could
remind us lt expect segment margin profil
give us better sens cartridg pull endosaf product
quantifi volum unit price
particular therapeut area see particular strength
book other
describ natur hire initi expertis made
particularli strong hire much wage pressur see
speak vision real-tim studi data track capabl client
envis function work way see attract
near term prioriti note youd readi anoth deal
target area
type opportun would find attract china standpoint
impact recent across larger pharma sponsor bmy/celg
cybersecur breach provid updat remedi effort
client sort financi impact expect
implic recent envigo/cov transact benefit sort
interest asset
much dental consum growth attribut underli market
dynam vs market share gains/loss see current market growth
rate consum na market sort visibl underli
consum demand trend across dental busi
think north america dental consum growth trend head
longer term guidanc assum term underli demand
term intern consum growth unpack dynam
across variou geographi particular bright spot surpris
think longer term growth opportun intern consum
specialti highlight bright spot intern growth speak
market posit across specialti categori expect differ
categori grow go forward level invest ortho implant
unpack america equip intern sale growth particularli
follow declin impact shift dentspli sirona world
vs underli driver lt equip growth
would character abil line sight margin expans next
speak one earli result ventur far demand
gener strategi expand adopt across practic
describ relationship differ across dso henri
schein one fit relationship
detail/provid background dso formulari manag effort
servic provid regard anticip abl
command price
updat dso re-contract head long contract typic
speak increment invest allud call
relationship distribut
seen evid greater direct sale initi manufactur
anyth chang increment posit neg relat opportun
sirona relationship rel initi expect
think emerg market strategi recent acquisit china
distributor thailand growth opportun brazil
amazon lot nois industri whether on-line retail may
provid viabl altern tradit distributor consum side
busi stanc issu amazon market share
initi thought xray new cerec primescan trio launch
remind us strategi relat proprietari product brand area
interest invest product better posit market
speak strength experienc implant term
premium versu valu growth come current
see greatest opportun
think strateg rational rel recent invest
three implant busi intra-lock medenti medic pro-cam
competit posit implant
speak reveal clear align system compar slx
product differenti product current expect
market plan posit product price traction assum
believ market opportun clear align segment given
clear domin player space conjunct least two
competitor enter space strateg rational enter market
youv note lack softwar penetr germani prevent bring
current offer germani best pathway gain foothold
speak broader sale trend chairsid vs stand-alone digit impress
seem disconnect underli util demand trend medic
report attribut share gain much runway
continu captur market share
provid color around recent trend medic see major
driver risk factor head
opportun one medic
margin differ medic dental give us sens
product mix medic highest margin product
key driver rel faster growth medic despit low volum
note paid credit facil cash inflow
think capit deploy light stronger balanc sheet
appetit larger deal
type deal interest pursu medic vs dental bolt-on vs
youv previous guid million tsa revenu still
line current think tsa revenu million recogn
help us think profit across gross margin
call spoke sale minor invest octob
embed guidanc help us think impact
well impact thereon minor interest
speak drive growth technolog value-
ad servic segment think growth trajectori nt
youv mention push sell higher margin privat label product talk
associ initi percentag current sale
would character current veterinari demand trend qtd reflect
guidanc longer term assumpt relat fundament demand
recent rais lower end organ growth outlook
primari driver revis
term preliminari guidanc speak underli
driver across dx lpd element conservat potenti risk
given ceo transit expens north america field forc expans
two new facil come on-lin think cadenc
margin expans bp ex ceo transit impact
sustain price dynam
quantifi overal nt lt opportun associ prevent care
initi primari barrier unlock valu sort initi
implement address tangibl datapoint track progress
much custom base use refer laboratori point care
dual-mod overlap trend metric go time
driver practic volum revenu strength track system
room run term broader demand growth util us
speak recent trend same-stor vet offic visit clinic visit practic
revenu base data track recent chang calcul methodolog
speak initi econom broader roll-out
sdma slide perform impress expect
contribut consum growth ramp time competitor wing
sedivu provid updat placement trend consum
util track traction compar intern expect
catalyst one see meaning step consum util similar
catalyst dx adopt experi thought core chemistri placement trend nt
equip placement trend quantifi upgrad opportun core chemistri
us typic replac cycl
thought rapid assay competit landscap vs first gener product
 much futur invest equip vs novel test vs
system new area test interest explor unmet need
think implic ztss entranc refer laboratori
market us
continu gain share us refer laboratori updat refer
laboratori competit landscap vs vca regional/academ player
acquir marshfield lab million revenu help us think
strateg ration vs organ invest pipelin updat similar deal
competit bid
think intern refer lab new sale forc effort ramp
refer lab strategi differ rel refer
laboratori strategi us current eu macro environ broader adopt
traction fecal antigen test refer lab
opportun improv refer laboratori profit thought recent dynam
vetconnect pet health network adopt stand
expect impact volum retent rate market share time
opportun better monet data asset
would character adopt trend digit radiographi capit equip
purchas trend vet clinic
rational behind new north america salesforc expans help us think
ramp new salesforc expect achiev optim product
direct distribut approach differ term cross-sel
promot activ bundl across refer lab in-hous
intern geographi target penetr
market today increment opportun better penetr across market
implic covetrus/vetsfirstchoic adopt work
updat relationship corpor account banfield
sustain market share posit growth higher margin segment
product launch new contamin outbreak would character
commit busi
speak key driver across livestock busi exposur lacklust
dairi end market african swine fever competit landscap
think long term growth rate lpd busi see
increment opportun potenti invest bovin genom similar area
lpd segment predominantli intern lpd sale see
opportun domest commit lpd effort
thought ztss acquisit abaxi last year competit landscap
evolv to-dat seen benefit disrupt market
zts/abax deal step taken maintain industri lead posit
may also move direct distribut model diagnost anticip
influenc purchas pattern rapid
decid longer provid longer term pipelin updat
competit respons primarili driven zts/abax transact
abil work veterinari clinic well plan pet health insur util
geograph area focu particularli strong underli veterinari
labcorp america lh
give us updat underli fundament util trend across core
clinic laboratori busi expect organ volum growth trend
earli thought
manag contract speak roll horizon
bcb volum progress thu far expect
prefer lab network sort impact anticip unh new
prefer lab network lt surpris limit number lab
spoke key contract win speak expect impact
contract top-line margin perspect provid color
contract support market posit
term beacon lb pilot non-renew florida spoke
bp impact revenu per requisit associ volum
impact broadli help us understand impact across
pama quantifi headwind expect relat clinic lab
fee schedul clf incorpor anoth round repric
hospit referr volum someth structur play
help us think perform view drove
weak dtc contribut volum rel expect
expect embed guidanc given last year surpris
calendar day dynam competit landscap profit dynam
think contributor volum growth go forward
rational behind john ratliff abrupt departur recent assign ceo lcd
think medicaid rate go forward continu expect
medicaid plan reduc rate in-lin medicar reduct
updat bcb florida contract potenti win dgx/open non-
think implic commerci rate light pama
updat acla pama lawsuit
think prospect lab act term timelin
likelihood get pass explain potenti impact lab act
comment chang see hospit insourc outsourc
trend would character current pipelin
market share vs rest market trend time
view longer term normal trajectori next year
give us updat walgreen relationship store
store lt see volum consist patient servic center test mix
post ttm btb recent quarter slight improv
help us understand underli dynam
histor basi consid btb metric healthi
think assumpt chang basi
speak seen recent term biotech fund rfp
well expect
initi place acceler voluntari opt-in clinic trial databas
new busi award relat combin services/data offer
recent open new center shanghai speak success
market to-dat offer driven new busi award
speak strateg rational envigo acquisit includ
purchas envigo preclin research servic busi sale covanc
research product busi alreadi embed guidanc term
contribut transact
investor question commit preclin busi prior envigo
deal vision busi segment longer term improv
overal posit covanc
speak strateg rational behind sciformix acquisit sort
opportun see cro offer pharmacovigil regulatori
solut space see opportun bolster cro offer
youv mention trial leverag combin data asset across
covanc labcorp busi speak custom feedback
offer provid metric help us think support drug
develop process client
opportun better leverag patient servic center build walgreen
relationship virtual trial concept
your divers custom mix limit exposur speak implic
broader pharma industri consolid
provid updat launchpad initi potenti acceler
even increas cost save
expect covanc adj ebit margin reach lt
compar preclin clinic competitor
speak launchpad phase ii focus lcd segment
think potenti cost cut opportun
capit deploy vs share repo embed guidanc
 pipelin see acceler discuss relat
pressur industri pama/mco contract shift
weve posit clinic laboratori inform technolog play
commod servic provid appropri rel busi mix/futur
monet vast amount data collect cours
oper lab busi area data could provid use
synergi outsid cro space
view offer light data-driven offer
marketplac
walk us key growth driver throughout rest year would
character fundament demand trend outlook progress
note ntp suppli issu allevi slightli thank one supplier
abil increas product capac give us updat suppli disrupt
statu supplier anticip suppli issu relat gross
margin pressur flow
give us updat pend progen deal addit color deal
rational pipelin updat expect close
updat repriorit pipelin consid addit progen
updat progen pipelin
speak competit landscap ultrasound contrast market defin
opportun extend product life-cycle
speak defin initi europ new partnership bring
defin italy/portugal/spain achiev meaning traction intern
give us updat potenti meaning chang reimburs
environ across core product line
defin rt next step defin rt complet
qualif batch remind us relationship samsung
elabor competit landscap room temperatur contrast agent
lvef note lvef indic doubl defin market opportun
walk us think size opportun speak
trial progressing/timelin
lmi fda grant orphan drug design use lmi
neuroendocrin tumor august note possibl elig rare pediatr
diseas prioriti give us updat pipelin prioriti
approv
flurpiridaz speak next develop catalyst trial enrol
quantifi market opportun
china market entri updat packaging/tri delay doubl crane
see opportun
manufactur speak on-going manufactur invest still expect
invest weight toward profit implic longer term
intern contrast ultrasound societi petit fda remov black
ultrasound contrast agent label impact demand/util trend
updat defin ip specif pertain patent expir come year
speak competit landscap molybdenum
speak ansto new facil think help
sourc suppli time
make bwxt announc abl bring technetium-
product market competit posit
speak new xenon competit entrant differ competit
entrant past relev geographi
discuss contract strategi nuclear product technelite/xenon
contract volum versu prior year
think cerevast relationship applic beyond ocular
updat us current rfp environ recent win rate
rfp environ chang outlook see acceler
rfi convert rfp think peer see environ given
differ custom mix
think model revenu basi given volatil
pass-through quarter-to-quart project-to-project basi btb
new target
would character current smid biopharma demand biotech fund
environ given exposur segment color recent custom pipelin
sort visibl intermediate/lt goal double-digit revenu
growth initi particular expect drive
potenti opportun larg pharma custom remain
focu ampl opportun smaller biotech leverag core compet
across nich
speak current price environ everyon behav ration
differ custom segment
differ book polici compar
impact book-to-bil backlog convers metric
speak natur recent cancel expect revenu
headwind elev cancel subsid
speak natur new busi win latest quarter look
therapeut custom mix disproport larger contract
influenc new busi win
custom therapeut mix evolv next year
speak current custom concentr portion new award
come exist custom compar new custom
therapeut area focu particular categori see longer
studi start-up time complex therapeut area exposur exposur influenc
backlog convers trend seen industri constitu
discuss key differ exclus full-servic busi
model functional/piecem work full-
servic model impact growth potenti long-term margin profil
risk appetit moder think limit downsid busi
plan continu see strong book environ perhap
favor seen recent year
leverag data asset improv win rate speed start-up
competit landscap your compet new busi see
competitor tabl mayb unconvent player typic would see
specif regard larg tradit focu smid
lt target ebitda margin mind think quarterli
progress profit go speak increment invest
hire expect throughout year success gotten ahead hire
current cra retent rate contribut better profit
trend locat cincinnati hurt help
opportun improv effici across central lab busi
walk us softer margin guid gross margin sg stop
lt margin remain elev level
headcount grown y/i past four quarter trend start
taper normal hire rate look like
view fix price model cro industri specif
someth could offer futur
term central lab busi provid updat see
demand perspect extent demand growth driven core full-
servic outsourc offer invest offer
previous mention stepped-up invest central lab busi
elabor initi think fit long-term return
histor acquisit could chang
think capit deploy prioriti elimin lt debt
would ever seller obvious right price theori acquir
larger cro exclus full servic would impact busi
provid updat infrastructur invest remind us
rational make invest time
light consolid across biopharma anticip volatil across
busi would busi impact larger custom engag
dso profil current dynam differ custom segment
call indic long-term leverag ratio think
 evalu potenti opportun term size industri
character on-going dynam product anim demand trend differ
domest intern market
challeng dairi market mention see stabil
give color drive whether think stabil
continu impact omnigen sale
mention pivot dairi strategi gain market share provid
product larg scale cow dairi farm rather cater small dairi
farm give us color strategi progress
updat omnigen traction product
think demand trend across poultri swine dairi next
african swine fever impact china
mention million headwind busi
essenti equat entireti china sale impact seen
date seen offset yet term increas demand
offset market
see benefit larger amount us export pork china
zoeti point new commerci polici cattl brazil headwind
benefit
updat work develop asf vaccin mention
multibillion dollar market size size market
insight possibl timelin
note custom order pattern impact mfa give
color whether think chanc may continu next
talk foray companion anim provid color
expect busi
feel need scale readili compet companion
anim market compet use one-off product
talk in-licens companion anim technolog
platform complet product readi go-to-market
rejensa success far trial distribut period
color timelin top-lin impact product
expect entri companion anim go beyond lyme diseas project
kind project could expect
broadli speak new product current develop key
area invest see meaning opportun certain therapeut
class speci
give color timelin invest strateg initi
think impact beyond spend frontend load
would character underli demand trend categori
headwinds/tailwind incorpor guidanc expect
impli guidanc
expect chang mix profit versu part
world mention unstabl intern econom condit impact anim
busi possibl break fx impact
expect mitig effect antibiot regul potenti
regulatori environ becom challeng us intern
market mention product compar favor standard
greater opportun intern
give us updat osprey integr acquisit progress
upcom pipelin develop highlight
speak traction omnigen europ china commentari
state us dairi competit dynam
view intern market pocket strength vs weak
outlook weak vaccin driven market
quantifi exposur viginiamycin
speak consumer-driven pressur busi
across miner nutrit busi clarifi impact sale gross
margin commod price increases/decreas
updat mecadox visibl fda request
traction magni-phi poultri nutrit specialti product
divestitur perform product busi
updat aquacultur initi
could provid littl bit color loss distribut agreement
earli fiscal start lap come quarter
provid color could get back double-digit growth vaccin
nutrit specialti anyth last two quarter chang longer term
outlook busi
volum price dynam
think put take organ volum growth
provid updat volum transit light
recent contract shift line potenti ahead expect
think unh/horizon volum impact much
increment volume/shar captur contract follow first full-year
access
think potenti opportun relat part unitedhealth
prefer clinic laboratori network overal intent pln
think impact longer term surpris number lab
chosen part prefer lab network
expect payor adopt prefer lab network go forward
wait see dynam larger-scal adopt could broader use
prefer network mean broader lab industri
unh prefer lab network differ previous util
criteria consid pick prefer lab provid
provid color incentiv patient physician
see increment pressur commerci insur use clf price
refer point much manag care contract essenti lock
next sever year
youv mention insur live consid in-network vs last
year would character constitu cohort
sizabl residu exclus competitor
provid updat pama relief effort progress
think introduct lab act hous
repres like pass view sens
timelin would look like
also speak acla effort pama relief effort particularli follow
submiss alca brief potenti outcom
previous experienc stepped-up patient concess earlier year
end last year patient concess trend recent
drive dynam speak y/i headwinds/tailwind experienc
thu far patient concess dynam expect impact
test denial major headwind lab busi help us think
lap denial vitamin hep etc
expect similar chang payor reimburs polici year may driver
explain reclassif bad debt vs patient concess
stand safeway partnership mani store
current partner evolv next year
expect expans safeway comfort
relationship current stand see volum loss transit shut
made progress addit basic healthcar servic youv talk
provid locat provid color point
possibl would partner addit compani part retail initi
limit safeway forese futur
speak quest direct offer help us understand better posit
market earli adopt progress custom feedback
updat site care initi innov
guid cost save year invigor program
initi progress rel expect much captur thu far
help us better understand cost save realiz across
relat potenti monet data potenti work other
pharma compani updat signific type
opportun well-posit think marketplac vs
competitor vs labcorp in-hous cro
 pipelin look like right see import
opportun pursu
recent mention deal convers timelin elong due
complex scope size deal drive convict abl
continu achiev contribut longer term
recent announc new profession lab servic pl agreement cathol
health servic long island remind us pl strategi
support overal growth strategi posit market
pipelin look like type deal
see increas pace deal progress increas potenti deal
given pama primarili hospit outreach lab space see
independ lab well
would character current fundament dynam product anim
busi relat contraction/expans herd size feed cost cattl feed
relev variabl think speci segment
next coupl quarter beyond overal exposur
insight consum spend trend given current macroeconom environ
industri trend see current companion anim market
posit vet util trend weve experienc sustain pet ownership trend
guidanc impli organ growth excl fx
anticip shift strategi ceo transit anticip
associ manag chang
speak strateg rational behind recent acquisit phoenix central
laboratori deal mark shift diagnost expans strategi toward
domest vs intern focu strategi lean toward similar
acquisit organ initi servic combin two
would consid ad intern refer laboratori offer
provid updat abaxi integr combin sale forc effort
report million abaxi revenu estim
maintain guidanc abaxi contribut bp oper top-lin growth
drive confid contribut legaci abaxi perform
us rel expect market
livestock diagnost opportun envis timing/magnitud
potenti upgrad instal base abaxi instrument provid
updat chemistri analyz develop well pipelin opportun
acquir smb
provid updat simparica trio approv timelin us could
label includ puppi indic beyond heartworm intern parasiticid
indic anticip
simparica trio approv europ updat
upcom launch timelin thought compet nexgard spectra
countri surpris regard approv indic
quantifi current size flea/tick/heartworm market opportun
expand market product like simparica trio cannib
speak recent launch versican bb oral new canin oral vaccin
europ product differenti thought market opportunity/s
plan launch brand gener version elan rumensin next year
anticip compet huvepharma brand gener version
competit landscap draxxin anticip gener competitor near-term
thought norbrook new gener ceftiofur embed guidanc
anticip entrant
speak market opportun proheart cannib proheart
product help round parasiticid portfolio
speak market opportun inject flea/tick/heartworm product
speak market opportun revolut cat traction-to-d
apoquel opportun aggress price product quantifi
market potenti across acut vs chronic under-penetrated
guidanc impli term atop dermat growth
veterinarian prescrib apoquel vs cytopoint level cannib
seen
thought competit landscap atop dermat view
competit threat kindr product much abl bundl
apoquel cytopoint help compet new entrant
top prioriti collabor regeneron mab
updat rimadyl competit landscap potenti offset sort
strategi take bundling/promot standpoint relat rimadyl
traction swine vaccin current market share
provid updat pharmaq underli fundament across
aquacultur opportun recent agreement pharmaq
vinh hoan vietnam
altern antibiot product explor potenti non-antibiot anti-
infect peptid stand develop process
 dollar dedic novel therapeut vs life-cycle enhanc
frame market opportun chronic felin pain critic unmet need
contribut front could peak sale potenti product go
exposure/impl african swine fever china
concern regard recent tyson ractopamin ban ractopamin
geographi see largest opportun near term companion
product anim altern area deemphas
australia see market improv near term year drought
repres increment opportun market turn
vfd compar european regul well regulatori dynam
market expos product consumer-driven pressur
gross margin go longer term driver
structur initi ahead plan progress front could
upsid downsid risk guidanc relat cost structur initi
profit differenti livestock vs companion
annual price realiz longer term sustain
open establishing/ establish direct relationship e-
commerc platform chewi thought type direct distribut
relationship impact econom map price polici
rational behind use distributor vs direct sale forc certain product
switch distribut vaccin parasiticid vs direct sale
continu abaxiss plan go direct exclus leverag
distributor dognost
distribut simparica trio direct distribut
pricing/exclus relationship larger veterinari chain distributor particularli
updat relationship corpor account
walk us two salesforc expans long take
new salesperson ramp follow expans rational expans
recent disclos sourc product manufactur
vs grey market shift occur implic busi
thought view broader implic newer concept
capit deploy opportun near term dividend hike de-lever
aggress share repurchas billion author remain
expect broader industri consolid anim continu
expect competit landscap look like near term longer term kindr
chang landscap recent merger impact creat new
opportun challeng sale forc defect
work capit improv near term address high inventori day sap
implement influenc
anticip sell-sid day decemb
intern investig color context provid intern investig
potenti misstat previous report foreign exchang gain loss
momentum maintain posit improv trajectori first half
expect cc growth momentum carri
key headwind tailwind think head next year
medic deliveri give confid achiev medic deliveri
goal provid updat small- large-volum iv solut
well intern feel state market think
uptak spectrum iq infus pump evo iq ou rest
year also updat us instal pump base
chang market share trend
renal drive strong patient volum pd process
resolv suppli constraint associ revaclear dialyz
expect resolv also provid updat capit invest
increas product capac home dialysi
acut therapi updat us roll-out prismax next-gener
technolog crrt progress key market plan
enter
pharmaceut drive demand hospit pharmaci compound servic
product specif drive demand gener inject drove lower
anesthesia critic sale last quarter provid updat myxredlin
insulin product expect gain share drive mix acute-car insulin
segment updat us revenu opportun myxredlin
clinic nutrit key new product drive growth clinic
nutrit busi track launch clinolipid proprietari oliv oil-bas lipid
emuls year market opportun product
advanc surgeri perform advanc surgeri benefit competit
suppli constraint long expect suppli constraint continu benefit
element help drive continu growth segment
margin make progress drive margin higher current
key margin expans opportun intermedi term long term
capit alloc think current market environ
type potenti invest interest key
challeng face find attract strateg asset
tax fx polit trade key factor affect effect tax rate
next month strategi employ manag fx trend
clearli remain headwind deeper year affect
perform factor debat see play head
presidenti elect could affect end market either favor
headwind opportun bsc array growth driver opportun
underway pipelin youv face seri headwind
challeng recent degre taken focu what work
intermedi long-term opportun walk us near-
term concern weight substanti temper investor
expect see pipelin growth opportun
potenti offset issu
tavr provid updat lotu edg launch
expect market share gain progress enrol repris iv
 clinic trial expand indic intermediate-risk patient pleas updat us
 acur trial well next-gen eu acur launch walk
us expect acur growth affect scope clinic data
long
watchman updat us timelin bring watchman flx
provid updat enrol option post-abl patient asap
contra-ind patient trial clinician feedback flx europ
launch watchman japan progress
btg provid updat btg integr process help us understand
btg intervent grow dd plan divest licens busi
plan divest spec pharma also could disrupt mil cost synergi
target next three year
endoscopi number recent product launch driven strong endoscopi growth
think endoscopi growth next month
long-term expect busi
driver think acceler growth
busi still track launch lux-dx icm
provid updat mcrm system track start
enrol
exalt-d set launch exalt-d single-us duodenoscop year-end
think signific factor variabl affect ramp
competit dynam expect oversea think
bil market opportun
oper margin give confid achiev bp oper
margin expans annual import contributor margin expans
gross margin improv sg effici product
think btg oper margin profil go forward contribut corpor
capit alloc given recent btg close integr smaller tuck-in
acquisit still expect next year area interest
challeng face find attract asset environ
learn anyth acquisit past year
unexpect challeng gone better expect
tax fx polit trade key factor affect effect tax rate
next month strategi employ manag fx trend
clearli remain headwind deeper year affect
perform factor debat see play head
presidenti elect could affect end market either favor
 tavr one key driver us tavr growth report
highlight unexpect bolu tavr treatment follow strong
data tell bolu ramp new higher run rate us tavr
strategi relat new center chang sinc new ncd forthcom
growth tavr low-risk patient
tavr market growth trend magnitud long-term opportun
earn call posit strength creat challeng
us tavr market growth term difficult year-over-year comparison
current stand term market penetr plan
updat investor long-term view market given recent strength
earli tavr long-term tavr opportun updat us
enrol earli tavr trial factor caus push expect
complet enrol
ou tavr make tavr market europ differ
reimburs price competit landscap much eventu carri
 much idiosyncrat european market japan
like like europ key driver
tmtt give confid tmtt sale doubl key growth
driver next month key challeng
mitral valv repair share commerci roll-out pascal eu
disclos premium price strategi region say would reassur
investor right approach provid updat pace strategi
enrol clasp pivot studi pascal
investor expect potenti legal hurdl affect time launch
pascal cardioband becom time-effici repair system
mitral valv replac albeit earli updat us sapien evoqu
mitral valv replac program track initi pivot trial
year high level expect one platform ultim
winner investor think valv system complementari
transcathet tricuspid repair drove decis acceler pascal tricuspid
pivot trial expect term time plan initi
second tricuspid pivot trial cardioband
surgic structur heart drive growth inspiri resilia aortic valv
surpris launch premium valv still expect european
regulatori approv harpoon system year-end
margin investor expect make progress drive margin
higher near term key margin expans opportun
intermedi term long term
capit alloc think current market environ
type potenti invest interest key
challeng face find attract strateg asset
tax fx polit trade key factor affect effect tax rate
next month strategi employ manag fx trend
clearli remain headwind deeper year affect
perform factor debat see play head
presidenti elect could affect end market either favor
 spine growth share gain globu alway wed call fast
innov help drive above-market growth share gain past
year robot surgeri platform also enhanc growth spine
busi look recent share gain growth vs market grow
low singl digit much gain think driven uptak pull-
robot vs globu globu
imag ortho globu surpris investor nass new intern develop
imag system repres competitor o-arm
surpris investor two month earlier acquisit ortho implant manufactur
stelkast goal unveil robot surgeri system orthopaed
investor put new growth driver perspect much increment
invest requir tell us magnitud invest
enabl technolog plan leverag experi
excelsiusgp spine surgeri enter market markets/ind
potenti target think competit environ
still wit longer decis make cycl hospit execut level
track launch interbodi modul quarter plan spine
trauma pleas updat us trauma launch mani set place
field rep recruit think ramp
beyond
ebitda youv consist deliv ebitda margin on-going
invest robot surgeri trauma imag intermediate- long-term growth
opportun given breadth recent announc growth program
investor expect ebitda margin lower middl upper end
competit rep hire current tone competit rep hire
environ stabil becom challeng critic
growth continu expand distribut anyth tell
us think need potenti youll get
capit alloc think current market environ
type potenti invest interest key
challeng face find attract strateg asset
growth talk top-lin growth css major
compon drive above-market growth new product launch
import factor percentag sale css driven new product
introduct vs core portfolio
lt sale target talk achiev bil revenu within next three
year help us understand drive much expect
mil run rate china japan within css
think growth profil css ou go forward updat us
recent launch duragen japan think opportun
residu integr day country-typ challeng investor mind
cusa clariti expect sale cycl cusa clariti lengthen result
addit competit enter segment base current adopt trend cusa
current mix capit vs consum envis go
next year
neurosurgeri drive growth neurosurgeri busi
think neurosurgeri growth head low-to-mid-singl digit rang
forese major headwind
tsa bulk heavi lift done codman tsa last
remain day countri css expect close anyth
els major left japan tsa expect transit japan day
two countri improv oper leverag
tma provid updat transit manufactur agreement tma
expect exit agreement transit manufactur
product iart facil
ebitda pleas outlin major put take achiev ebitda margin
time exit tma benefit margin profil
major driver investor focus
 recent acquir two early-stag technolog platform
rebound help us understand rational behind acquisit
complement exist css portfolio expect gener
revenu ep accret think capit alloc go
perspect past year challeng opportun look ahead
complet first year ceo share thought youv
learn organ compani end-market surpris
would say greatest opportun critic challeng
next year next year
what special spine come spine rel
outsid spent career one might call enabl technolog
end gener surgeri spectrum would convey make spine
compel challeng market given debat differenti
disrupt aspect defens platform compani
peopl technolog strategi would highlight investor one might say make
special
recent growth nuva spinal hardwar elabor drove
strong growth spinal hardwar think head
next year expect continu momentum key driver
new product think new product introduct relev
drive above-market growth share gain drive uptak
nuva procedur what special porou titanium peek product
right time expand cervic offer
puls provid updat puls beta evalu recent ce mark
approv puls think puls launch ou see
major obstacl uptak puls robot platform could derail
robot spine surgeri thought current state robot spine
surgeri think market look like five year import clinic
evid adopt
step take improv set avail apac
latam pleas updat us long-term expans plan doubl ou
revenu make intern spine market uniqu compar
complex spine plan take share bil complex spine market
far get organ type strateg invest would help acceler
growth area
biolog give confid biolog return growth
think biolog busi go forward
 surgic support walk us busi key growth
margin strategi busi drive synergi core implant
enabl technolog line expect evolv roll-out puls
robot surgeri applic
oper margin key driver long-term adjust oper
margin target think margin progress next five year
import manufactur effici in-hous manufactur initi
achiev goal
capit alloc look beyond complex spine area within spine
see opportun expand portfolio strateg invest
mask last quarter grown well excess double-digit growth
rate market high-single-digit growth rate attribut growth
much growth came new mask much growth come re-
suppli market share gain due innov mask drive higher complianc
better re-suppli program long think continu gain share mask
concern competit environ new launch
competitor strategi combat competit pressur
strategi ensur continu growth re-suppli see limit
far re-suppli get new mask price vs new
mask price vs competitor new mask launch row countri
much new mask contribut growth row
devic growth us devic also elev gain share
market grow quicker estim market share competitor
price sit rel industri volum growth current trend sleep test
neg impact chang reimburs franc japan
underli basi growth row expect growth
return normalis level row penetrated/und penetr vs us
tri growth market row countri key
gross margin given strong us mask growth perform continu market share
gain mask vs devic posit gross margin high gross margin go
oper leverag seen signific oper leverag
last coupl year point get oper effici
anticip continu benefit come
us competit bid dme put bid round competit
bid new rate come effect jan anticip happen
rate scenario lower mask devic reimburs rate
respond
saa matrixcar brightre integr go integr
two platform underli growth rate brightre growth come
market share brightre dme market share matrixcar post acut saa
space expect see synergi base busi verili
go anticip start see profit still expect oei loss
propel mani partner agreement
anticip reach commercialis integr product rest
portfolio trial pharma compani base around
get payer approv want use softwar platform propel
offer big respiratori vs sleep acquisit anyth
miss portfolio saa portfolio say financi attract
revenu earn contribut
despit report result ahead expect compani updat full-year
outlook thought wonder would abl speak
decis factor play
also lot macroeconom concern even cite driver
pressur stock curiou get thought medicar
result includ mln tail revenu mln associ ifp busi
mln associ medicar busi expect head
respect tail revenu believ mention mln ifp
busi understand guy gener dont expect much tail revenu
tail revenu exceed intern expect translat
similar level beat ebitda tail revenu pass
think tail revenu model tail revenu level
similar around mln
remind use mani agent current new agent
product go licens train carrier
appoint etc seen pick-up product newli
hire agent guidanc assum new agent best
product think residu benefit vs
compani note call custom care enrol expens includ
cost associ licens train carrier appoint etc understand
care enrol expens per approv member goe sequenti
absolut amount custom care enrol expens item model amount
sequenti
variabl market expens medicar busi grew y/i compar
growth approv medicar member compani invest margin
direct on-line demand gener channel higher market cost acquisit
also tend higher unassist on-line convers elabor
kind lead refer
know still earli stage annual enrol period
seen data point hint toward strong
comment around ltv y/i versu prior
expect mid-singl digit attribut less switch sign-up
cohort sinc earn call alway thought expect around ltv
driven expect switch due new oep wonder
churn impact ltv expect peopl abl
switch outsid oep
remind us percentag member switch plan move onto
anoth platform mani switch still stay platform
also talk initi focus effort recaptur
expect ltv assum similar y/i switch
churn better current expect would favor impact
ltv
compani report pretti stabl medicar turnov rate rang trail
month basi way think implic trend member turnov rate
averag durat assumpt ltv calcul
compani note call expect year-over-year growth approv medicar
member approv medicar member y/i
first nine month impli y/i growth approv member
think approv member medicar advantag particular
particular
on-line order fulfil gener percentag on-line
enrol picks-up season expect
still expect percentag order fulfil full year
view competit landscap market new entrant
medicar market exist player make push etc know highli
fragment larg market seen chang competit environ year
speak revenu ebitda shortfal drove
much shortfal expect recov futur quarter
cob busi compani highlight payer system prepar
handl claim elig transact gener compani call two
pbm system issu larg region payer problem
handl medicaid claim pbm relat compani industri
go busi transit
respect larg region payor system issu think
chang futur quarter
continu work enhanc cob growth leverag machin learn
autom product develop real-tim insur identif
elig verif solut understand alreadi real-
time insur identif capabl elabor enhanc
compani focus
comment last earn call cob busi expand
medicar advantag medicar part commerci market well essenti
leverag exist payer relationship busi line
reiter mid-singl digit y/i revenu growth full-year impli
close y/i growth understand expect shortfal
revers still y/i growth would signific revers growth
rate busi seen year thought
begin integr sale overal commerci sale
forc compani note call approach work compani
plan compani attain sale target far year result
refin go-to market strategi rebuild sale team focus sole
includ hire new sale leadership talent expect drive
increment expens
restructur impact abil gain fair market share
addit implic compani abil cross-sel
product across busi segment
sign second at-risk eliza deal quarter larg nation payer
compani upsid potenti base achiev certain key perform
indic effect performance-bas contract like skew
season busi fourth quarter
base compani updat guidanc seem longer expect analyt
servic busi pi tpm y/i grow doubl digit rate long-term
still expect busi return growth rate chang long-
provid color ebitda margin third quarter exclud
mln gain invest adjust ebitda margin primarili
function neg leverag associ revenu pressur
unusu expens quarter pressur ebitda margin
talk increas invest provid updat
invest think return invest
talk million invest medadvisor lead digit educ
manag compani australia approxim ownership stake manag
note call australia uk market compani focus
see market focu market potenti opportun futur
talk initi around integr latest technolog
innov ai telehealth offer
earn call citi client util high
curiou provid color
seen higher util middl market employ rather larg employ
color provid would great
respect compani comment around rfp book
reason may necessarili translat revenu growth
gross margin clearli came better expect anyth particular
would like highlight drove out-performance quarter
guidanc assum gm moder
drove sequenti pick-up advertis market expens
respect comment around contract compani note pmpm
would ex- contract versu report figur seem
impli pmpm mln fee-bas live around think
right would impli mln annual revenu contribut fee-
thought think util rate remain mln
live visit fee contract think compani get
mid-singl digit util rate think rel gradual ramp
contract price structur across board like fix fee plu
visit fee kind hybrid model given relationship aetna make
lot sens would extend relationship busi well color
aetna telemedicin offer
aetna contract teladoc expir end read anyth
fact parti dont updat agreement yet
know give guidanc yet current consensu impli y/i
revenu growth re-affirmed lt revenu growth
probabl ok howev consensu also impli ebitda margin
versu give heartburn think compani
enough margin expans driver
comment peter resign
addit look compani seem jason employ
agreement amend includ bunch addit provis termin
caus addit color
field lot question investor compani mayb begin
want provid high level overview livongo mayb expand four main
talk relationship health expans
hypertens segment talk client ad servic
also follow know fortun compani alreadi use livongo
diabet wonder captur remain
sell solut middle/smal size compani revenu split
look
regard recent announc integr virtual care platform mdlive
 doctor demand color share primari
incent compani launch offer see grow
speak high level behavior health segment see
busi line grow initi livongo keep
thought competit landscap hard would
compani come today disrupt industri given chang dynam color
would great
compani choos focu chronic condit diabet prediabet
hypertens etc also work weight manag wonder exactli
develop mystrength see busi grow
thought look like know bit earli
curiou see start look ahead
elabor retrofit acquisit merg
compani strategi toward anyth look
expand offering/servic know recent expand area
wonder field may look
see enrol diabet member grow also comment
ad addit client know past quarter year year basi grew
curiou thought livongo approach new
speak analyt livongo offer custom
interfac also term popul come abl gener
enrol main driver behind
wonder breakdown price structur
employe pay noth also livongo data collect
david fletcher telehealth geising not-for-profit
begin would abl speak background high level
overview telehealth geising
research around telehealth would abl share walk us
process compani goe start new project
talk telemedicin offer differ other
look add featur extra servic
wonder could get thought opinion geising
behavior health space also see market progress
elabor provennavig emphasi prevent servic
servic telehealth fit program perform
far color would help
speak work compani done medicar
space telehealth offer segment well
util geising incent look
implement alreadi increas util
look demograph breakdown user telemedicin
trend seen
use provid telehealth select other
look explor anoth idea opportun add telehealth walk us
process geising goe
given recent announc beigen collabor think
opportun xgeva blincyto kyproli china
could talk regulatori access dynam china
think beigen collabor differ youv
encount chines pharmaceut market
strategi integr otelza compani structur term market
salesforc
provid detail repatha launch progress access
challeng improv commerci uptak aimovig
plan acceler aimovig uptak
given even recent posit opinion chmp view opportun
eu
remind us current approv biosimilar us eu progress
launch far
provid color market dynam biosimilar oncolog vs inflamm
speak commerci opportun tezepelumab timelin bla
omecamtiv phase trial heart failur think
timelin potenti launch commerci opportun
differ competitor attribut want
still subject think durabl next data
endpoint would like see nsclc
area would area interest pipelin expans
share repurchas program fit strateg capit alloc
strategi base success would will continu strategi
strategi place maintain eylea leadership posit wet light
intensifi competit beovu biosimilar eylea posit
jv recent becom profit driven mainli strong perform dupix
point plan reduc spend under-perform asset like praluent
step taken prepar potenti outcom healthcar reform
latest perspect use intern price index outcom
expect implic busi
eylea see opportun growth strategi realiz
growth expect greater focu diabet indic eylea
current strategi investor expect term growth
dupix label expans improv opportun expect next
month event investor radar
roll-out chronic rhinosinus nasal polyp could help give us
sens much growth see indic
sort opportun appeal bd perspect expect
collabor approach interest acquir fulli unencumb asset
greater interest late stage commerci asset asset earlier develop
libtayo roll-out progress need happen us see acceler
expect initi bcma data later year stand
program what next asset next year
provid updat collabor work teva fasinumab
think potenti opportun garetosmab
row
walk us opportun evinacumab
program pipelin would like highlight
discuss
across portfolio catalyst read-out investor watch
lesson kalydeco symdeko launch appli trikafta
given trikafta broad label give us sens commerci opportun
patient expect cf center priorit first
think trikafta launch term growth attribut new patient
versu growth attribut cannib kalydeco orkambi symdeko
plan offer sort education/awar program highlight side
effect nuanc orkambi symdeko
remind us statu gain reimburs franc given recent
uk spain deal plu trikafta approv think help acceler potenti
agreement franc
next cf franchis given treat cf patient
plan work toward treat patient
desir protein level program earli
think commerci opportun
think market opportun crispr program
thalassemia sickl cell diseas
focus still crispr program given smaller number program data
disclosure/clin approach differ program run
talk semma deal fit overal strategi
opportun see outsid cf franchis
much prioriti brine later stage asset pipelin see
trikafta launch play role support futur capac
speak macro-environ large-cap biotech compani given
asset pipelin upcom event would like highlight
consid recent discuss drug price gener thought
could impact
franchis key catalyst next year could reduc relianc jakafi
could talk opportun see jakafi gvhd progress
payor recept cover jakafi gvhd
besid expand chronic indic type benefit could
reach trial add jakafi label gvhd
think posit jakafi gvhd given clear
consensu treatment
decid best avail therapi jakafi
type increment opportun could expand label chronic patient add
size market opportun see itacitinib much could asset add
feel capmatinib help divers revenu consid receiv
feel dermatolog franchis fit within tradit focu
could walk-u thought commerci topic ruxolitinib in-hous
type opportun see pemigatinib see think fit
commerci landscap given recent approv balversa
type opportun see parsaclisib given challeng seen
biolog differ parsaclisib b-cell malign nhl fl mzl
mcl vs dlbcl could potenti show better result
consid area focu challeng opicapon commerci roll-out
opicapon differ drug class
continu commerci expans ingrezza td key factor
allow continu achiev new patient start
continu focu ingrezza see patient switch
expect patient switch meaning part commerci ramp
persist discontinu chang throughout
new inhibitor differ ingrezza particular
neurologic/psychiatr disord focus indic
speak expect program
still focus program enter phase adult see key
endpoint goal efficaci safeti
talk orilissa expans uterin fibroid expect see
impact
see opportun orilissa expand indic
talk relationship voyag particular entri gene
much role neurocrin play development/market vy-aadc
think market opportun vy-aadc gene therapi
continu focu voyag relationship provid detail
walk us recent updat phase sophia trial margetuximab
patient breast cancer
kind feedback receiv physician data particularli
month improv overal surviv
think posit margetuximab given crowd breast
could walk us data gastric cancer
could remind us current treatment paradigm gastric cancer expect
posit margetuximab
could see drug move earlier line therapi
indic margetuximab look plan explor
next step program
franchis talk molecul current develop
strategi
give confid target right approach
could updat us program plan posit drug
made adcom think rem program
palforzia includ
addit detail share interact fda sinc
sort financ need ahead palforzia launch
sort spend ramp expect compani move commerci
plan ex-u next step program outsid unit state
term build commerci capabl
major mileston left launch
could pleas describ natur collabor nestl plan
deepen partnership
latest thought price sort interact payer
feedback far
provid updat phase clinic trial egg allergi
result would like see trial
pathway registr upcom catalyst
awar
walk us market opportun
plan commerci surround would requir addit
salesforc familiar allergi
success would consid expand ex-u
allergi close relat peanut perhap experi
may lead explor similar approach
luspatercept refractori md td b-thal
fda accept luspatercept bla transfus depend beta thalassemia
esa refractory/inelig md expect fda requir adcom
level confid approv question anticip fda
character recent interact
outlin xlrn/celg agreement respons rel
celgen term agreement outlin go-to-market
commerci strategi md compar go-to-market strategi b-
think potenti launch trajectori luspatercept approv
see differ potenti launch trajectori md vs b-thal
think rel posit luspatercept rel agent
develop b-thal mention specialist treat md
academ center mani patient specialist manag mani trial site
clinic trial walk actual administr drug
home clinic comp would point term price
character recent payer discuss expect drug reimburs
medicar part part
walk us md competit landscap includ drug current
use treat diseas agent develop
provid updat front-lin md studi command non-
transfus depend b-thal beyond studi power command
suggest might explor luspatercept indic walk
broader luspatercept strategi look futur diseas
recent announc top-lin myelofibrosi mf data summar data
think saw greater benefit combin ruxolitinib vs monotherapi
particularli light seen sotatercept mf addit data
expect actual present think next step
program plan explor agent mf broadli patient alreadi
help us understand market opportun specif mani patient are/ar
ruxolitinib are/ar transfus depend think
durat therapi mf rel md walk agent
develop mf outlin potenti differenti drug
rest pipeline/corpor
sotatercept moa differ current avail pah treatment give
confid sotatercept potenti effect agent pah would
sotatercept fit rel crowd pah landscap expect sotatercept
administ home clinic
sotatercept two trial pah walk design two
studi look see studies/what see clinic meaning
support advanc program studi proceed base
pulsar studi wait spectra studi result evalu next
step number earlier approv pah base provid
perspect potenti approv today rang endpoint
may consid potenti
plan top-line result cmt look see
support continu develop program recent discontinu
fshd expect compani similarli decis one way
respect program
walk long-term pipelin strategi think intern
 develop rel bd
walk result help contextu
placebo correct chang urinari oxal level mean patient see greater
efficaci particular patient segment think high placebo
rate trial
addit run separ studi walk
design trial power trial quickli
expect studi enrol quickli trial take enrol
abil expand trial enrol
patient develop kidney stone frequent typic kidney
stone biggest predictor develop anoth kidney stone
urinari oxal level factor well think
relationship urinari oxal level kidney stone binari
continuum goal get peopl normal rang order see benefit
reduct even patient normal meaning
strategy/timelin explor drug patient ckd
expect file timelin expect initi label
expect initi label includ detail drug impact kidney stone format
fda indic particular urinari oxal lower threshold want
see support acceler file acceler approv base pure
primari endpoint fda indic base approv primari secondari
think price drug data accumul clinic
trial think aid price discuss payer
potenti market comp would point instanc thiola reason comp
least term fit within treatment paradigm acknowledg cystinuria much
less common enter hyperoxaluria payer manag access thiola
expect similar restrict drug
expect compliance/discontinu rate drug
base expect
think uptak label potenti includ inform
drug impact kidney stone format
believ slide indic nephrologist urologist us
curiou identifi subset high-prescrib physician sens
mani patient treat doc
look like oxthera oxazym explor hyperoxaluria back
time-frame happen know data studi also know
happen program
expect uc/cd market evolv oral launch frame
advantag disadvantag etrasimod moa vs jak-inhibitor etrasimod
rel posit versu agent therapeut class ozanimod expect
competit balanc shift potenti develop selective/restrict jaki
may offer cleaner safeti profil
discuss timelin expect uc cd program youv laid
ambiti clinic trial plan rel small compani lay step your
take meet intern enrol goal pretti competit set conduct trial
anyth avoid delay issu sometim seen enrol
asset target ibd speak aggress develop plan cd
differ develop plan within space expect
updat fda decis support adapt design fda requir
tradit develop plan would impact timelin
basi decis advanc etrasimod ad expect
efficaci set rel uc crohn would look efficaci
move program forward note ad also competit arena conduct trial
think develop strategi etrasimod given
previous state possibl applic indic evalu outlin
overal criteria take indic clinic think balanc new
program versu priorit later stage/larg market effort drug
consid potenti price differenti develop decis long-term ip
strategi etrasimod
ibd/ib patient experi pain outlin spectrum sever
olorinab would fall treatment paradigm drug patient
respond current therapi prospect drug util top
current treatment option avail
would regulatori path look like olorinab would follow path similar
linzsess larg studi popul would enrol
provid color patient characterist degre
patient receiv prior pharmacolog non-pharmacolog pain therapi
enrol similar patient
mechanist character olorinab decreas inflamm extent
 compar modal nsaid
beta antagonist gate step file ind
still earli would expect develop asset broadli decompens heart failur
opportun select develop potenti higher price point shorter
time market
emerg data seem suggest efgartigimod could favor toler
profil rel mab target fcrn much evid suggest
differenti could explain fc region effector function mab sinc
optim minim function
fc fragment proven superior approach defens argenx posit
competitor attempt develop fragment-bas product much protect
expect base patent and/or know-how
exclus deal halozym util enhanz technolog
develop sc product recap sc dose strategi expect product
profil sort bridg studi requir indic
disclos addit detail dosing/pow on-going phase
studi disclos detail baselin characterist patient enrol
gener compar confirm length infus
disclos mani dsmb meet occur
recommend chang protocol
expect competit landscap evolv competit versu
complement inhibitor even fcrn antagonist play
chang mg-adl seem key registr endpoint program gmg
expect efficaci consid efgartigimod competit
cidp disclos term trial design least inclus criteria
trial patient expect fcrn antagon abl address
consid autoantibodi fulli character signific portion
discuss choic primari endpoint iv itp studi much
inform durabl given novelti expect active/pbo arm
give us detail power
second itp trial discuss pk/pd work youv done expect
abl keep patient remiss sc dose
long patient ole dose new find
indic increasingli competit multipl oral agent avail
develop includ btk inhibitor recap realist commerci
opportun class efgartigimod within fcrn class
compani seem reluct develop fcrn antagonist pv
give us thought case commerci posit
expect efgartigimod potenti pv
anti-drug antibodi efgartigimod studi date shown rel high anti-drug
antibodi rate often compar placebo potenti explan
high rate assay limit complic
provid addit inform scd-saf test
fda sign tell us would posit
pleas explain determin appropri dose level trial
describ new safeti inform contribut enabl expand
current studi scd patient older plan run futur
trial younger pt expand address popul
spoken fda regulatori path forward outlin
would necessari acceler approv pathway
sgc amen diseas would consid studi olinciguat
think price strategi much price point
novarti drug weigh decis
recap recent clinic updat program updat us potenti
partnership discuss base addit feedback think
clinic meaning result dn studi
outsid els expect see top-line readout
expect hear indic endeavor studi well
walk long-term pipelin strategi indic
consid organ-target therapi
sgc stimul activ produc encourag preclin data variou
diseas fail replic data clinic give convict
compound effect human
could talk potenti competit product activ acinetobact could
util on/off-label type infect durlobactam target
choos current develop pathway durlobactam instead
typic cuti/ciai indic work expand
trial execut expect see contribut zai lab
expect diagnost tool help identifi patients/spe enrol
think commerci opportun durlobactam establish
type commerci infrastructur believ necessari target
hospitals/cent high rate carbapenem-resist acinetobact
thought likelihood/prospect consolid antibiot space
high-prob near-term initi may improv reimburs offer
incent brand product anti-infect sector
provid updat regard research focus neisseria gonnorhoea
ultim envis zoliflodacin molecular platform reach need
underdevelop region access issu may awar would
limit drug us commerci right frame approach
see qc rang recent approv clsi use
futur non-gonnorhoea organ
provid overview efficaci safeti bemedpo acid trial
lt safeti studi death imbal unrel treatment ba arm
give confid outcom spuriou outlin saw
safeti perspect term ae sae rate discontinu rate
rate lft trial compar approv ldl-c
outlin saw term reduct trial
hypothesi mechanist perspect see benefit see
weight gain edema
file approv base ldl-c improv current run
long-term outcom studi briefli walk design trial give
confid ldl-c reduct hscrp improv translat
clinic success cvot studi expect time result cvot
studi way tri reduc risk studi well valid
hscrp biomark
character recent fda interact area focu
respect applic
fda recent announc hold adcom amarin drug announc
came fairli late review process see read-through
much safeti data fda want see number patient length follow-up
fix dose combin pill prior approv much safeti data expect
time
target ldl-c per treatment guidelin evolv
one market segment target patient statin intoler
character statin intoler mean mani patient us meet
outlin plan differenti therapi therapi
market develop expect out-of-pocket cost
bempedo acid compar uptak rate
sinc compani announc lower price
put context recent ba data patient hypercholesterolemia type
diabet data fit broader strategi ba
think launch trajectori see amarin launch good
comp think cvot impact ba commerci trajectori and/or pharma
interest asset
help us understand sg cost associ launch
bempedo acid instanc larg sale forc expect need etc
speak current balanc sheet posit expect runway
term eu partnership plan partner japan region
recent sign us royalti partnership part oberland dilig process
review fda minut
walk long-term pipelin strategi statu ba
upcom registr trial dlbcl expect popul similar
articul regulatori path forward provid detail
potenti bar fda warrant acceler approv highlight specif
threshold respons orr cr specif point time analysi
treatment landscap clinic pipelin dlbcl evolv frame
think could potenti fit treatment paradigm consid class
adc develop r/r popul size potenti
compare/contrast bar success potenti commerci opportun
indol lymphoma consid differ soc clinic pipelin
outlin commerci opportun md popul size
address popul unfit chemotherapi transplant receiv
futur plan studi lower risk md popul would
gate step conduct studi less sever popul
landscap evolv past year compani
depriorit program other enter clinic outlin see
posit across field see key differenti featur
assess competit program present data
give us sens data expect upcom ovarian
colorect cancer trial respons rate would consid compel enough
advanc program preliminari discuss fda regard
provid overview commerci opportun solid tumor program
pursu ovarian urotheli carcinoma posit data
posit work toward develop earlier-lin therapi r/r patient
focu across tumor
provid overview commerci opportun solid tumor program
pursu ovarian urotheli carcinoma posit data
posit work toward develop earlier-lin therapi r/r patient
focu across tumor
anti-ckit program recap competit landscap think
differenti potenti lower hang fruit commerci opportun
outlin refractori ntm patient portion
see address perspect annual incid
refractori diseas think revenu curv post treat
initi preval popul see term durat therapi
sens durat therapi non-respond month discontinu
treatment month stay therapi past point
term arikayc launch find clinician gener use
drug line label refractori ntm use
one area investor focu arikayc reimburs outlin mani
patient cover medicare/medicaid process get formulari
base launch date significantli payer manag arikayc use
averag patient out-of-pocket cost patient assist program
percentag patient cover insur plan arikayc
formulari think gross-to-net adjust today
expect chang arikayc brought formula
outlin arikayc safeti profil sinc launch compar
seen clinic trial expect process place
mitig risk possibl drug discontinu sure earli tell
sens discontinu track rel clinic trial
outlin number new start past coupl quarter see
stabil new start expect number new start increas
plan continu updat street new start part quarterli earn
next year metric focu inform allow
understand percentag non-convert continu therapi beyond
time new ntm treatment guidelin
statu time potenti eu jpn approv
mention seek eu approv follow jpn approv
eu price could use comp establish jpn price atu price
franc expect price arikayc europ
approv histor comp eu price jpn price
pah advanc copd ipf cf
outlin think sg cost initi front-
line studi build intern sale forc outlin current
commerci capabl term size sale forc ex-u plan
ad rep ahead launch region
provid detail timelin statu confirmatori studi
main gate step prior start confirmatori studi quickli expect
abl valid propos re-balanc st georg respiratori
balanc desir achiev profit versu maxim opportun
arikayc particularli ex-u build pipelin think
arikayc cog consid strateg partnership ex-u
perspect intern develop vs select bd healthi sg
infrastructur built import leverag
walk time updat earlier stage pipelin
result look see support continu improv
degre confid result
walk decis develop vivo ex vivo gene edit capabl
two platform complement outlin strategi
respect select therapeut target select attr vivo sickl cell ex
vivo aml ex vivo first program ip posit
outlin on-going litig broad institut uc
outlin rang edit made use edit
easier make outlin indic address kind
edit far away make complic edit gene insert
front outlin preclin gene insert data present recent
preclin present found blunt-forc gene insert effect
approach easi control degre express approach
outlin way bodi repair dna break way get
cell favor one repair mechan anoth advantag
disadvantag non-homolog end join homolog direct repair
one area investor focu differ deliveri vehicl use
outlin advantag disadvantag use lipid nanoparticl vs aav
vivo gene edit platform lipid nanoparticl use target tissu besid
liver outlin lipid nanoparticl degrad long
process take
outlin step take mitig potenti off-target effect
seen off-target effect preclin studi differ approach
outlin regeneron novarti agreement cover area
exclus right current balanc sheet posit think
futur collabor
outlin ip portfolio provid updat variou ip proceed
activ
provid addit insight consecut knockout insert present
esgct
lead program ttr outlin observ preclin
studi efficaci perspect well valid ttr knockdown relat
function benefit degre ttr knockdown clinic meaning mani
month follow-up much variabl respons see
safeti signal provid updat statu toxicolog studi
sever drug approv ttr space outlin market
opportun ttr valu proposit offer patient
mention plan nomin candid aml quickli
nomin candid could enter clinic walk data gener
date program
sinc new technolog provid perspect term
mani year data fda want see approv gene edit therapi
main area focu regul
on-going clinic studi investig gene-modifi tcr therapi md
aml patient expect result curiou
familiar studi thought construct design
see potenti read-through aml program
elabor regard attr program durabl liver
edit result ttr protein reduct consist confid
nhp singl dose translat human therapi
shed light timelin support futur trial regard aml
guid total revenu put take
term think revenu could come linzess us sale astella
agreement etc instanc think astella revenu move forward
base recent chang agreement expect price
pressur rel patient out-of-pocket cost averag
number competitor ibs-c space strategi
combat competit pressur area potenti differenti see
indic see opportun grow market speak
initi undertak
recent data linzess ibs-c evidenc improv overal
abdomin symptom data fit overal market strategi
plan get data onto label time potenti snda
walk ip portfolio linzess
walk mechan action drug drug similar
moa explor gerd result
walk data data seen mg
outlin saw mg dose dose
respons happen follow patient discontinu drug
return baselin term heart burn sever
heart burn sever assess rate heartburn respond patient
ppi respons rate chang time chang heartburn sever
walk design trial provid quick updat
statu trial power studi expect placebo
respons good public would point relat
earn call report trial enrol slower expect
reason difficulti recruit patient restrict inclusion/exclus criteria
step taken improv recruit mani trial site
character market opportun well central treatment
refractori gerd center excellence/group treat particularli high
number patient mani patient treat center
think pricing/ar comp would point toward
differ ibs-c ibs-d pathophysiolog level
walk us therapeut hypothesi key differ linzess
walk us design trial view clinic
meaningful/what look see support move program studi
would point term give confid trial
character market opportun competit landscap
speak think balanc profit versu develop pipelin
intend build pipelin would intern effort bd
speak broader pipelin strategi
key takeaway ole studi result seen date
administ studi patient need dose start dose
dose wasnt endpoint ole close correl
think chang lvot gradient nyha function class peak
chang rate sever applic atrial fibril ole
expect rate atrial fibril patient popul
mavacamten explor studi ohcm result expect
outlin design trial walk us dose adjust
process studi decis dose-adjust determin
blind studi protocol chang suggested/impl
follow data safeti monitor committe review frequent safeti review
conduct tell us safeti trial thu far
similar popul explor pioneer studi
expect baselin lvot gradient trial rel trial
baselin compar averag baselin ohcm popul
expect patient higher gradient see greater benefit given
obstruct vice versa
normal degre variat would expect peak nyha function
class natur histori studi power studi mani
pioneer patient achiev primari endpoint trial
optim dose titrat explor reason expect even higher respond
rate
expert suggest would like treat symptomat ohcm
patient walk us epidemiolog diseas help us understand
address market expect doc want use mavacamten patient
diagnos symptomat ohcm expect use confin second-lin
set would popul look like frame think
reason sanofi termin collabor agreement cover
mavacamten sever earlier stage agent recent announc
bought back us royalti right mavacamten up-front next year
competit process
awar studi evalu impact alcohol ablation/surgeri peak
degre improv endpoint observ
think potenti price mavacamten data
collect support case
provid overview trial expect time data
differ diseas burden obstruct non-obstruct diseas
talk expert mention improv pioneer may driven
diastol function gradient improv think respect
degre benefit compon compar baselin peak
key diastol biomark measur nohcm trial
much inher variabl endpoint look see
nohcm trial deem success give confid
abl see benefit week
success nohcm set think futur develop
mavacamten -- run nohcm studi and/or would consid explor
mavacamten broader diastol dysfunct heart failur popul
success potenti better address unmet need
recent announc data briefli outlin efficaci safeti data
clinic meaning stroke volum improv character
asymptomat mild transient increas troponin see associ
dose troponin elev time point troponin elev occur
initi result hand next step program expect
need run outcom studi support approv endpoint
form basi approv
outlin mechan action differenti strategi rel
competitor outlin design endometriosi trial walk
clinic data mani patient report data week
see secondari endpoint patient global impress chang
strategi dose walk safeti
profil two differ dose
defin respond studi endpoint
compar explor competitor result compar elagolix
orilissa relugolix
statu linzagolix studi mani trial site
run mani trial site anticip trial
outlin view market opportun endometriosi degre
unmet need expect durat treatment
walk thought orilissa launch seem like littl
slower launch investor expect think
challeng
besid use add-back therapi see point differenti rel
orilissa price strategi
linzagolix also explor uterin fibroid current two trial
provid updat timelin data studi time regulatori
file give confid trial
frame market opportun uterin fibroid curiou hear expect
pace oral gnrh antagonist launch uterin fibroid expect
faster slower seen oral gnrh antagonist launch
plan commerci linzagolix consid potenti partner
asset
mani sale peopl need market linzagolix us
speak potenti call point would target mani clinician would
recent receiv oxford financ debt due august curiou
term contract requir repay sooner date
term speak current cash posit expect cash runway
outlin mechan action plan phase part
 data specif data disclos time
look see support continu develop program
help frame market opportun
signific investor focu risdiplam firefish sunfish sma trial
walk us time potenti data releas firefish part type
sunfish part type sma trial primari endpoint/do need
achiev firefish studi primari endpoint power
sunfish studi give confid achiev primari endpoint
baselin characterist studi compar studi
plan top-line sunfish/firefish result avail
wait releas initi data confer
plan present efficaci data beyond month sunfish type sma
part studi plan present updat risdiplam data trial
next month firefish jewelfish rainbowfish frame
data present look
present updat sma firefish part sma type sunfish
part data may octob outlin result
compar spinraza zolgensma help reconcil hammersmith scale
walk risdiplam safeti profil stand term
tox studi see tox issu high dose anim
remain track file approv us eu base
data supplement data main
gate step regulatori file expect word initi label
relat aadc defici program outlin clinic data date
gate step potenti fda file market opportun
aadc expect next updat patient identif effort
walk exact process identifi patient current
fa ind recent delay late reason
delay outlin gate step ahead ind enter
fa gene therapi program number differ deliveri method explor
preclin literatur system direct brain walk
pro con variou approach outlin hope see
function standpoint enter clinic later year tissu need
target safeti issu anim associ high frataxin express
larg dose window frataxin excret protein remain
cell level frataxin express think clinic meaning
revenu product earli pipelin
provid updat dmd busi outlin revenu growth rate
next year outlin growth driver translarna
emflaza ip statu product statu translarna
confirmatori studi eu market statu translarna dystrophin studi
tegsedi approv brazil next step respect obtain
reimburs expect peak latam opportun tegsedi
waylivra soon expect meaning tegsedi revenu
outlin ambiti develop strategi someth like new program
next year import view becom profit think
balanc profit vs pipelin develop
walk term agili acquisit variou mileston
think therapeut potenti microdystrophin compar
human dystrophin expect correl dystrophin express
normal function exampl patient level much higher rel first
three patient correspond efficaci addit nsaa function
assess comment util ck measur given high volatil
metric time four patient think ck reduct use tool
investor get preliminari gaug rel efficaci one therapeut versu anoth
biomark evalu may demonstr earli respons
help predict degre efficaci inform potenti durabl
differenti clinic program util
infus safeti sort issu encount manag post-infus
consid high dose gene tx test observ meaning lft
increas blood count chang need administ iv steroid
agent beyond protocol steroid prophi think high-dos system gene
therapi program like encount sae
would abl speak blind safeti profil studi
instanc platelet reduct kidney injuri etc discuss
rhabdomyolysi event disclos august patient dose describ
resolut event etc
walk chang design first trial
prompt chang power studi expect
mention plan run confirmatori trial use commerci scale
product gate step start trial expect term
form basi approv expect need function data
studi perform sort interim analysi evalu biopsi data
big pictur strategi address older younger patient trial
expect data studi
indic meet fda discuss design confirmatori
trial plan meet soon meet
plan updat street clear outcom expect fda instanc
fda tell support design least tell
support particular design
plan provid long-term data patient
expect data
outlin current mfg capabl stand term
manufactur build-out time commerci scale-up process much product would
like abl suppli launch import commerci first
market novarti recent announc price sma gene therapi zolgensma curiou
thought price therapi reimburs model go
use
elect dose escal trial earlier year drove decis
present data dose escal cohort factor determin
dose youd take forward
present initi function data low-dos patient gene
therapi studi speak chang nsad function
endpoint three patient month prior dose
time potenti discuss regul path forward
program well lgmd program potenti effici see
respect develop path timelin bring lgmd
program clinic
walk lgmd market opportun broadli lot
literatur publish lgmd outlin step undertak help
better understand rel spectrum diseas burden think pursu
multipl lgmd subtyp
gene tx multipl gene therapi program develop provid
updat statu program time potenti disclosur relat
